<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Viruses</journal-id><journal-id journal-id-type="iso-abbrev">Viruses</journal-id><journal-id journal-id-type="pmc-domain-id">1559</journal-id><journal-id journal-id-type="pmc-domain">viruses</journal-id><journal-id journal-id-type="publisher-id">viruses</journal-id><journal-title-group><journal-title>Viruses</journal-title></journal-title-group><issn pub-type="epub">1999-4915</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10144269</article-id><article-id pub-id-type="pmcid-ver">PMC10144269.1</article-id><article-id pub-id-type="pmcaid">10144269</article-id><article-id pub-id-type="pmcaiid">10144269</article-id><article-id pub-id-type="pmid">37112948</article-id><article-id pub-id-type="doi">10.3390/v15040968</article-id><article-id pub-id-type="publisher-id">viruses-15-00968</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Nationwide Laboratory Surveillance of Progressive Multifocal Leukoencephalopathy in Japan: Fiscal Years 2011&#8211;2020</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-7594-2607</contrib-id><name name-style="western"><surname>Nakamichi</surname><given-names initials="K">Kazuo</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/">Software</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><xref rid="af1-viruses-15-00968" ref-type="aff">1</xref><xref rid="c1-viruses-15-00968" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Miura</surname><given-names initials="Y">Yoshiharu</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="af2-viruses-15-00968" ref-type="aff">2</xref><xref rid="fn1-viruses-15-00968" ref-type="author-notes">&#8224;</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Shimokawa</surname><given-names initials="T">Toshio</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/">Software</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><xref rid="af3-viruses-15-00968" ref-type="aff">3</xref><xref rid="fn1-viruses-15-00968" ref-type="author-notes">&#8224;</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Takahashi</surname><given-names initials="K">Kenta</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="af4-viruses-15-00968" ref-type="aff">4</xref><xref rid="fn1-viruses-15-00968" ref-type="author-notes">&#8224;</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Suzuki</surname><given-names initials="T">Tadaki</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="af4-viruses-15-00968" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Funata</surname><given-names initials="N">Nobuaki</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="af5-viruses-15-00968" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Harada</surname><given-names initials="M">Masafumi</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="af6-viruses-15-00968" ref-type="aff">6</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Mori</surname><given-names initials="K">Koichiro</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="af7-viruses-15-00968" ref-type="aff">7</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sanjo</surname><given-names initials="N">Nobuo</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="af8-viruses-15-00968" ref-type="aff">8</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Yukitake</surname><given-names initials="M">Motohiro</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="af9-viruses-15-00968" ref-type="aff">9</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Takahashi</surname><given-names initials="K">Kazuya</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="af10-viruses-15-00968" ref-type="aff">10</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hamaguchi</surname><given-names initials="T">Tsuyoshi</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><xref rid="af11-viruses-15-00968" ref-type="aff">11</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Izaki</surname><given-names initials="S">Shoko</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="af12-viruses-15-00968" ref-type="aff">12</xref><xref rid="af13-viruses-15-00968" ref-type="aff">13</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Oji</surname><given-names initials="S">Satoru</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="af13-viruses-15-00968" ref-type="aff">13</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Nakahara</surname><given-names initials="J">Jin</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="af14-viruses-15-00968" ref-type="aff">14</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-2660-530X</contrib-id><name name-style="western"><surname>Ae</surname><given-names initials="R">Ryusuke</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="af15-viruses-15-00968" ref-type="aff">15</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-1050-2699</contrib-id><name name-style="western"><surname>Kosami</surname><given-names initials="K">Koki</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="af15-viruses-15-00968" ref-type="aff">15</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Nukuzuma</surname><given-names initials="S">Souichi</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="af16-viruses-15-00968" ref-type="aff">16</xref><xref rid="fn2-viruses-15-00968" ref-type="author-notes">&#8225;</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-6654-1481</contrib-id><name name-style="western"><surname>Nakamura</surname><given-names initials="Y">Yosikazu</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="af15-viruses-15-00968" ref-type="aff">15</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Nomura</surname><given-names initials="K">Kyoichi</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="af13-viruses-15-00968" ref-type="aff">13</xref><xref rid="af17-viruses-15-00968" ref-type="aff">17</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kishida</surname><given-names initials="S">Shuji</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="af18-viruses-15-00968" ref-type="aff">18</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Mizusawa</surname><given-names initials="H">Hidehiro</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><xref rid="af19-viruses-15-00968" ref-type="aff">19</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-2416-5662</contrib-id><name name-style="western"><surname>Yamada</surname><given-names initials="M">Masahito</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><xref rid="af20-viruses-15-00968" ref-type="aff">20</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Takao</surname><given-names initials="M">Masaki</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><xref rid="af21-viruses-15-00968" ref-type="aff">21</xref><xref rid="af22-viruses-15-00968" ref-type="aff">22</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ebihara</surname><given-names initials="H">Hideki</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="af1-viruses-15-00968" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-5458-7298</contrib-id><name name-style="western"><surname>Saijo</surname><given-names initials="M">Masayuki</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><xref rid="af1-viruses-15-00968" ref-type="aff">1</xref><xref rid="af23-viruses-15-00968" ref-type="aff">23</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Contini</surname><given-names initials="C">Carlo</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-viruses-15-00968"><label>1</label>Department of Virology 1, National Institute of Infectious Diseases, Shinjuku-ku, Tokyo 162-8640, Japan; <email>hebihara@niid.go.jp</email> (H.E.); <email>masayuki.saijo@doc.city.sapporo.jp</email> (M.S.)</aff><aff id="af2-viruses-15-00968"><label>2</label>Department of Neurology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Bunkyo-ku, Tokyo 113-8677, Japan; <email>yoshiharu_miura@tmhp.jp</email></aff><aff id="af3-viruses-15-00968"><label>3</label>Department of Medical Data Science, Graduate School of Medicine, Wakayama Medical University, Wakayama 641-8509, Japan; <email>shimokaw@wakayama-med.ac.jp</email></aff><aff id="af4-viruses-15-00968"><label>4</label>Department of Pathology, National Institute of Infectious Diseases, Shinjuku-ku, Tokyo 162-8640, Japan; <email>tkenta@niid.go.jp</email> (K.T.); <email>tksuzuki@niid.go.jp</email> (T.S.)</aff><aff id="af5-viruses-15-00968"><label>5</label>Department of Pathology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Bunkyo-ku, Tokyo 113-8677, Japan; <email>nobuaki_funata@tmhp.jp</email></aff><aff id="af6-viruses-15-00968"><label>6</label>Department of Radiology, Tokushima University School of Medicine, Tokushima 770-8503, Japan; <email>masafumi@tokushima-u.ac.jp</email></aff><aff id="af7-viruses-15-00968"><label>7</label>Department of Radiology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Bunkyo-ku, Tokyo 113-8677, Japan; <email>momosan0929@gmail.com</email></aff><aff id="af8-viruses-15-00968"><label>8</label>Department of Neurology and Neurological Science, Tokyo Medical and Dental University Graduate School of Medical and Dental Sciences, Bunkyo-ku, Tokyo 113-8510, Japan; <email>n-sanjo.nuro@tmd.ac.jp</email></aff><aff id="af9-viruses-15-00968"><label>9</label>Department of Neurology, Kouhoukai Takagi Hospital, Okawa-shi 831-0016, Fukuoka, Japan; <email>yukitake@b1.bunbun.ne.jp</email></aff><aff id="af10-viruses-15-00968"><label>10</label>Department of Neurology, Hokuriku Brain and Neuromuscular Disease Center, National Hospital Organization Iou National Hospital, Kanazawa-shi 920-0192, Ishikawa, Japan; <email>takahashi.kazuya.nx@mail.hosp.go.jp</email></aff><aff id="af11-viruses-15-00968"><label>11</label>Department of Neurology, Kanazawa Medical University, Kahoku-gun 920-0293, Ishikawa, Japan; <email>gom56@kanazawa-med.ac.jp</email></aff><aff id="af12-viruses-15-00968"><label>12</label>Department of Neurology, National Hospital Organization Saitama Hospital, Wako-shi 351-0102, Saitama, Japan; <email>izaki.shoko.dn@mail.hosp.go.jp</email></aff><aff id="af13-viruses-15-00968"><label>13</label>Department of Neurology, Saitama Medical Center, Saitama Medical University, Kawagoe-shi 350-8550, Saitama, Japan; <email>osatoru@saitama-med.ac.jp</email> (S.O.); <email>drno@saitama-med.ac.jp</email> (K.N.)</aff><aff id="af14-viruses-15-00968"><label>14</label>Department of Neurology, Keio University School of Medicine, Shinjuku-ku, Tokyo 160-8582, Japan; <email>nakahara@a6.keio.jp</email></aff><aff id="af15-viruses-15-00968"><label>15</label>Division of Public Health, Center for Community Medicine, Jichi Medical University, Shimotsuke-shi 329-0498, Tochigi, Japan; <email>shirouae@jichi.ac.jp</email> (R.A.); <email>k.kosami@jichi.ac.jp</email> (K.K.); <email>nakamuyk@jichi.ac.jp</email> (Y.N.)</aff><aff id="af16-viruses-15-00968"><label>16</label>Department of Infectious Diseases, Kobe Institute of Health, Kobe-shi 650-0046, Hyogo, Japan; <email>s-nuku@gj8.so-net.ne.jp</email></aff><aff id="af17-viruses-15-00968"><label>17</label>Higashimatsuyama Municipal Hospital, Higashimatsuyama-shi 355-0005, Saitama, Japan</aff><aff id="af18-viruses-15-00968"><label>18</label>Department of Neurology, Narita Tomisato Tokushukai Hospital, Tomisato-shi 286-0201, Chiba, Japan; <email>s-kisida@biscuit.ocn.ne.jp</email></aff><aff id="af19-viruses-15-00968"><label>19</label>Department of Neurology, National Center Hospital, National Center of Neurology and Psychiatry, Kodaira-shi, Tokyo 187-8551, Japan; <email>mizusawa@ncnp.go.jp</email></aff><aff id="af20-viruses-15-00968"><label>20</label>Division of Neurology, Department of Internal Medicine, Kudanzaka Hospital, Chiyoda-ku, Tokyo 102-0074, Japan; <email>m-yamada@kudanzaka.com</email></aff><aff id="af21-viruses-15-00968"><label>21</label>Department of Laboratory Medicine, National Center Hospital, National Center of Neurology and Psychiatry, Kodaira-shi, Tokyo 187-8551, Japan; <email>msktakaobrb@ncnp.go.jp</email></aff><aff id="af22-viruses-15-00968"><label>22</label>Department of General Internal Medicine, National Center Hospital, National Center of Neurology and Psychiatry, Kodaira-shi, Tokyo 187-8551, Japan</aff><aff id="af23-viruses-15-00968"><label>23</label>Medical Affairs Department, Health and Welfare Bureau, Sapporo-shi 060-0042, Hokkaido, Japan</aff><author-notes><corresp id="c1-viruses-15-00968"><label>*</label>Correspondence: <email>nakamich@niid.go.jp</email></corresp><fn id="fn1-viruses-15-00968"><label>&#8224;</label><p>These authors contributed equally to this work.</p></fn><fn id="fn2-viruses-15-00968"><label>&#8225;</label><p>Current address: Research Laboratory, KinoPharma, Inc., Kyoto 615-8245, Japan.</p></fn></author-notes><pub-date pub-type="epub"><day>14</day><month>4</month><year>2023</year></pub-date><pub-date pub-type="collection"><month>4</month><year>2023</year></pub-date><volume>15</volume><issue>4</issue><issue-id pub-id-type="pmc-issue-id">433445</issue-id><elocation-id>968</elocation-id><history><date date-type="received"><day>23</day><month>3</month><year>2023</year></date><date date-type="rev-recd"><day>11</day><month>4</month><year>2023</year></date><date date-type="accepted"><day>12</day><month>4</month><year>2023</year></date></history><pub-history><event event-type="pmc-release"><date><day>14</day><month>04</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>29</day><month>04</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-05-26 16:25:14.303"><day>26</day><month>05</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; 2023 by the authors.</copyright-statement><copyright-year>2023</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="viruses-15-00968.pdf"/><abstract><p>Progressive multifocal leukoencephalopathy (PML) is a devastating demyelinating disease caused by JC virus (JCV), predominantly affecting patients with impaired cellular immunity. PML is a non-reportable disease with a few exceptions, making national surveillance difficult. In Japan, polymerase chain reaction (PCR) testing for JCV in the cerebrospinal fluid (CSF) is performed at the National Institute of Infectious Diseases to support PML diagnosis. To clarify the overall profile of PML in Japan, patient data provided at the time of CSF-JCV testing over 10 years (FY2011&#8211;2020) were analyzed. PCR testing for 1537 new suspected PML cases was conducted, and 288 (18.7%) patients tested positive for CSF-JCV. An analysis of the clinical information on all individuals tested revealed characteristics of PML cases, including the geographic distribution, age and sex patterns, and CSF-JCV-positivity rates among the study subjects for each type of underlying condition. During the last five years of the study period, a surveillance system utilizing ultrasensitive PCR testing and widespread clinical attention to PML led to the detection of CSF-JCV in the earlier stages of the disease. The results of this study will provide valuable information not only for PML diagnosis, but also for the treatment of PML-predisposing conditions.</p></abstract><kwd-group><kwd>cerebrospinal fluid</kwd><kwd>JC virus</kwd><kwd>laboratory surveillance</kwd><kwd>progressive multifocal leukoencephalopathy</kwd><kwd>real-time PCR testing</kwd></kwd-group><funding-group><award-group><funding-source>Research Committee of Prion Disease and Slow Virus Infection</funding-source></award-group><award-group><funding-source>Ministry of Health, Labour and Welfare, Japan</funding-source><award-id>20FC0201</award-id><award-id>23FC1007</award-id></award-group><award-group><funding-source>JSPS KAKENHI</funding-source><award-id>21K07450</award-id></award-group><funding-statement>This work was supported by the Research Committee of Prion Disease and Slow Virus Infection, Research on Policy Planning and Evaluation for Rare and Intractable Diseases, Health and Labour Sciences Research Grants, the Ministry of Health, Labour and Welfare, Japan (grant nos. 20FC0201 and 23FC1007), and by JSPS KAKENHI (grant no. 21K07450).</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-viruses-15-00968"><title>1. Introduction</title><p>Progressive multifocal leukoencephalopathy (PML) is a rare but devastating demyelinating disorder caused by JC virus (JCV). JCV is a relatively small virus with a circular double-stranded DNA genome and is classified in the <italic toggle="yes">Polyomaviridae</italic> family [<xref rid="B1-viruses-15-00968" ref-type="bibr">1</xref>,<xref rid="B2-viruses-15-00968" ref-type="bibr">2</xref>,<xref rid="B3-viruses-15-00968" ref-type="bibr">3</xref>,<xref rid="B4-viruses-15-00968" ref-type="bibr">4</xref>]. The International Committee on Taxonomy of Viruses recently adopted the binomial nomenclature <italic toggle="yes">Betapolyomavirus secuhominis</italic> as the species name of this virus [<xref rid="B5-viruses-15-00968" ref-type="bibr">5</xref>]. However, the common virus name JC virus is still registered [<xref rid="B6-viruses-15-00968" ref-type="bibr">6</xref>]. JCV typically infects individuals during childhood and establishes persistent asymptomatic infection in the kidneys and urinary tract, as well as latent infection in other sites, such as lymph nodes and bone marrow [<xref rid="B2-viruses-15-00968" ref-type="bibr">2</xref>,<xref rid="B7-viruses-15-00968" ref-type="bibr">7</xref>,<xref rid="B8-viruses-15-00968" ref-type="bibr">8</xref>,<xref rid="B9-viruses-15-00968" ref-type="bibr">9</xref>,<xref rid="B10-viruses-15-00968" ref-type="bibr">10</xref>,<xref rid="B11-viruses-15-00968" ref-type="bibr">11</xref>,<xref rid="B12-viruses-15-00968" ref-type="bibr">12</xref>]. JCV is widespread in humans, with approximately 60% of healthy adults being serologically positive for this virus [<xref rid="B13-viruses-15-00968" ref-type="bibr">13</xref>]. Non-pathogenic JCV with persistent or latent infection has a stable genomic DNA sequence and is referred to as the archetype [<xref rid="B14-viruses-15-00968" ref-type="bibr">14</xref>,<xref rid="B15-viruses-15-00968" ref-type="bibr">15</xref>].</p><p>In individuals with immunocompromised statuses, including those undergoing therapies that affect cellular immunity, JCV can reactivate and replicate in oligodendrocytes, leading to brain demyelination [<xref rid="B1-viruses-15-00968" ref-type="bibr">1</xref>,<xref rid="B16-viruses-15-00968" ref-type="bibr">16</xref>,<xref rid="B17-viruses-15-00968" ref-type="bibr">17</xref>,<xref rid="B18-viruses-15-00968" ref-type="bibr">18</xref>,<xref rid="B19-viruses-15-00968" ref-type="bibr">19</xref>]. The JCV responsible for causing PML has a hypervariable mutation with deletions and/or duplications in DNA sequences of the non-coding control region (known as the regulatory or transcription control regions) within the viral genome and is referred to as the prototype [<xref rid="B9-viruses-15-00968" ref-type="bibr">9</xref>,<xref rid="B16-viruses-15-00968" ref-type="bibr">16</xref>,<xref rid="B20-viruses-15-00968" ref-type="bibr">20</xref>,<xref rid="B21-viruses-15-00968" ref-type="bibr">21</xref>,<xref rid="B22-viruses-15-00968" ref-type="bibr">22</xref>,<xref rid="B23-viruses-15-00968" ref-type="bibr">23</xref>]. PML occurs in the presence of various immunosuppressive conditions, such as HIV infection, hematologic malignancies, and organ transplantation [<xref rid="B2-viruses-15-00968" ref-type="bibr">2</xref>,<xref rid="B16-viruses-15-00968" ref-type="bibr">16</xref>,<xref rid="B24-viruses-15-00968" ref-type="bibr">24</xref>,<xref rid="B25-viruses-15-00968" ref-type="bibr">25</xref>]. In the past decade, there has been an increase in the incidence of PML in patients receiving immunosuppressive or immunomodulatory therapies for autoimmune diseases [<xref rid="B1-viruses-15-00968" ref-type="bibr">1</xref>,<xref rid="B2-viruses-15-00968" ref-type="bibr">2</xref>,<xref rid="B24-viruses-15-00968" ref-type="bibr">24</xref>,<xref rid="B26-viruses-15-00968" ref-type="bibr">26</xref>,<xref rid="B27-viruses-15-00968" ref-type="bibr">27</xref>].</p><p>It is crucial to clarify the clinical features and predisposing conditions of PML to reduce its risk and improve diagnosis. However, in most cases, reporting the occurrence of PML to the government is not mandatory, except for drug-safety monitoring purposes. Despite comprehensive studies on PML with possible adverse events caused by pharmaceutical products [<xref rid="B28-viruses-15-00968" ref-type="bibr">28</xref>,<xref rid="B29-viruses-15-00968" ref-type="bibr">29</xref>,<xref rid="B30-viruses-15-00968" ref-type="bibr">30</xref>,<xref rid="B31-viruses-15-00968" ref-type="bibr">31</xref>,<xref rid="B32-viruses-15-00968" ref-type="bibr">32</xref>,<xref rid="B33-viruses-15-00968" ref-type="bibr">33</xref>,<xref rid="B34-viruses-15-00968" ref-type="bibr">34</xref>,<xref rid="B35-viruses-15-00968" ref-type="bibr">35</xref>,<xref rid="B36-viruses-15-00968" ref-type="bibr">36</xref>,<xref rid="B37-viruses-15-00968" ref-type="bibr">37</xref>,<xref rid="B38-viruses-15-00968" ref-type="bibr">38</xref>,<xref rid="B39-viruses-15-00968" ref-type="bibr">39</xref>], gathering comprehensive information on each PML case across Japan has been challenging. Historically, several strategies have been employed to identify and analyze non-reportable PML cases, including single-center chart reviews of empirical cases [<xref rid="B40-viruses-15-00968" ref-type="bibr">40</xref>,<xref rid="B41-viruses-15-00968" ref-type="bibr">41</xref>,<xref rid="B42-viruses-15-00968" ref-type="bibr">42</xref>,<xref rid="B43-viruses-15-00968" ref-type="bibr">43</xref>,<xref rid="B44-viruses-15-00968" ref-type="bibr">44</xref>], multicenter observational studies of patients primarily with targeted clinical conditions [<xref rid="B25-viruses-15-00968" ref-type="bibr">25</xref>,<xref rid="B45-viruses-15-00968" ref-type="bibr">45</xref>,<xref rid="B46-viruses-15-00968" ref-type="bibr">46</xref>,<xref rid="B47-viruses-15-00968" ref-type="bibr">47</xref>,<xref rid="B48-viruses-15-00968" ref-type="bibr">48</xref>,<xref rid="B49-viruses-15-00968" ref-type="bibr">49</xref>,<xref rid="B50-viruses-15-00968" ref-type="bibr">50</xref>], estimates based on searches of large-scale public databases containing relevant information [<xref rid="B51-viruses-15-00968" ref-type="bibr">51</xref>,<xref rid="B52-viruses-15-00968" ref-type="bibr">52</xref>,<xref rid="B53-viruses-15-00968" ref-type="bibr">53</xref>,<xref rid="B54-viruses-15-00968" ref-type="bibr">54</xref>,<xref rid="B55-viruses-15-00968" ref-type="bibr">55</xref>,<xref rid="B56-viruses-15-00968" ref-type="bibr">56</xref>,<xref rid="B57-viruses-15-00968" ref-type="bibr">57</xref>,<xref rid="B58-viruses-15-00968" ref-type="bibr">58</xref>], and literature or systematic reviews of individual case reports in related fields [<xref rid="B43-viruses-15-00968" ref-type="bibr">43</xref>,<xref rid="B47-viruses-15-00968" ref-type="bibr">47</xref>,<xref rid="B59-viruses-15-00968" ref-type="bibr">59</xref>,<xref rid="B60-viruses-15-00968" ref-type="bibr">60</xref>,<xref rid="B61-viruses-15-00968" ref-type="bibr">61</xref>,<xref rid="B62-viruses-15-00968" ref-type="bibr">62</xref>,<xref rid="B63-viruses-15-00968" ref-type="bibr">63</xref>,<xref rid="B64-viruses-15-00968" ref-type="bibr">64</xref>,<xref rid="B65-viruses-15-00968" ref-type="bibr">65</xref>,<xref rid="B66-viruses-15-00968" ref-type="bibr">66</xref>,<xref rid="B67-viruses-15-00968" ref-type="bibr">67</xref>,<xref rid="B68-viruses-15-00968" ref-type="bibr">68</xref>,<xref rid="B69-viruses-15-00968" ref-type="bibr">69</xref>,<xref rid="B70-viruses-15-00968" ref-type="bibr">70</xref>]. One of the most extensive and successful surveillance programs of PML was conducted by a research group in France. Joly et al. identified 584 patients with PML over the past decade in a nationwide population-based cohort study using the French national health insurance system database and demonstrated the characteristics of PML in France [<xref rid="B58-viruses-15-00968" ref-type="bibr">58</xref>]. However, collecting information on PML patients from public databases in Japan remains challenging.</p><p>The polymerase chain reaction (PCR) detection of JCV DNA in the cerebrospinal fluid (CSF) is a minimally invasive and reliable indicator of PML diagnosis [<xref rid="B71-viruses-15-00968" ref-type="bibr">71</xref>]. Quantitative real-time PCR testing for JCV in the CSF has been performed at the Department of Virology 1 of the National Institute of Infectious Diseases (NIID), Tokyo, Japan, since the fiscal year (FY) 2007 (from April 2007 to March 2008) [<xref rid="B72-viruses-15-00968" ref-type="bibr">72</xref>,<xref rid="B73-viruses-15-00968" ref-type="bibr">73</xref>,<xref rid="B74-viruses-15-00968" ref-type="bibr">74</xref>]. This PCR testing is part of a nationwide surveillance study on PML of the Research Committee of Prion Disease and Slow Virus Infection, which is supported by Health and Labour Sciences Research Grants from the Ministry of Health, Labour and Welfare, Japan. During PCR testing for JCV in the CSF, clinical information of patients suspected of having PML is collected from physicians using standardized questionnaires, and the incidence and characteristics of PML are analyzed (hereafter, &#8220;laboratory surveillance&#8221;). The prospective laboratory surveillance for PML has been ongoing without interruption and continues. Previously, the results of the study were reported for the start-up period from FY2007 to FY2010 (4 years from April 2007 to March 2011) [<xref rid="B72-viruses-15-00968" ref-type="bibr">72</xref>]. Additionally, since FY2016, an ultrasensitive PCR assay capable of detecting at least 10 copies of JCV DNA per mL of CSF has been implemented for the laboratory surveillance of PML [<xref rid="B75-viruses-15-00968" ref-type="bibr">75</xref>].</p><p>In this study, we conducted a comprehensive analysis of the characteristics of 1537 patients who underwent PCR testing for JCV in the CSF at the NIID, including 288 patients who tested positive, to clarify the overall profile of PML in Japan over the past 10 years (FY2011&#8211;2020).</p></sec><sec id="sec2-viruses-15-00968"><title>2. Materials and Methods</title><sec id="sec2dot1-viruses-15-00968"><title>2.1. CSF Specimens and Clinical Data</title><p>This study was approved by the Medical Research Ethics Committee for the Use of Human Subjects at the NIID (approval nos. 1248 and 1317) and was conducted in accordance with the ethical standards of the Declaration of Helsinki. Written informed consent was obtained from either the patients or their authorized representatives. An Internet-based support system for CSF-JCV testing at the NIID has been described previously [<xref rid="B72-viruses-15-00968" ref-type="bibr">72</xref>,<xref rid="B75-viruses-15-00968" ref-type="bibr">75</xref>,<xref rid="B76-viruses-15-00968" ref-type="bibr">76</xref>]. We received requests for CSF-JCV testing from the patients&#8217; physicians for the diagnosis of PML nationwide, primarily through two websites (available in Japanese only): [<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://prion.umin.jp/pml/virus.html">http://prion.umin.jp/pml/virus.html</uri>] and [<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.niid.go.jp/niid/ja/from-vir1/9458-vir1-div3.html">https://www.niid.go.jp/niid/ja/from-vir1/9458-vir1-div3.html</uri>] (accessed on 3 March 2023). CSF samples collected from patients suspected of PML based on neurological findings and/or magnetic resonance imaging (MRI) patterns were sent to the Department of Virology 1 of the NIID for routine real-time PCR testing for JCV without charge to patients, except for shipping costs. At the time of PCR testing for CSF-JCV, anonymous patient information, such as age, sex, underlying disease, clinical findings, and previous treatment history, was collected by the treating physicians using standardized questionnaires.</p></sec><sec id="sec2dot2-viruses-15-00968"><title>2.2. Real-Time PCR Testing for JCV in the CSF</title><p>From FY2011 to FY2015, the standard PCR assay described previously [<xref rid="B72-viruses-15-00968" ref-type="bibr">72</xref>,<xref rid="B77-viruses-15-00968" ref-type="bibr">77</xref>,<xref rid="B78-viruses-15-00968" ref-type="bibr">78</xref>] was used to quantitatively detect JCV in CSF samples. Total DNAs were extracted from the CSF samples using a QIAamp DNA Blood Mini Kit (Qiagen, Venlo, Netherlands) or a QIAamp Viral RNA Mini Kit (Qiagen) and were subjected to a real-time PCR assay targeting the JCV large T gene. This standard PCR test had a lower detection limit of 200 copies of JCV per mL of CSF [<xref rid="B77-viruses-15-00968" ref-type="bibr">77</xref>]. Subsequently, in FY2016&#8211;2020, an ultrasensitive PCR assay was introduced as described previously [<xref rid="B75-viruses-15-00968" ref-type="bibr">75</xref>], which improved the detection efficiency by highly concentrating JCV DNA during nucleic acid extraction. This allowed for PCR testing with a detection limit of 10 copies/mL by concentrating viral particles in CSF samples with ultrafiltration. The ultrasensitive PCR assay for CSF-JCV was performed according to the procedures described in a previous paper [<xref rid="B75-viruses-15-00968" ref-type="bibr">75</xref>], with some modifications. In this study, the Roche LightCycler 96 System (Roche Diagnostics, Mannheim, Germany) was used for real-time PCR instead of the older generation of glass capillary-type instruments. PCR cycles were set according to the manufacturer&#8217;s protocol, and the annealing temperature was the same as described before [<xref rid="B77-viruses-15-00968" ref-type="bibr">77</xref>]. Additionally, a pUC19 plasmid containing the EcoRI fragment of the JCV Mad-1 strain genome (hereinafter, pMad-1-cl3) was used as standard DNA instead of a BamHI fragment lacking part of the end of the T gene. The PCR detection of JCV in the CSF with a lower limit of 20 copies/mL was routinely performed for ultrasensitive testing. An ultrasensitive JCV test with a detection limit of 10 copies/mL, including the additional step of concentrating JCV particles in the CSF by ultrafiltration, was performed in patients with multiple sclerosis (MS) or when a weak signal was observed in other cases.</p></sec><sec id="sec2dot3-viruses-15-00968"><title>2.3. Statistical Analysis</title><p>The correlation between the numbers of the study population and patients with JCV-positive CSF in the national distribution was evaluated using Spearman&#8217;s rank correlation coefficients. In addition, we performed a hierarchical cluster analysis of the regional proportions of patients with JCV-positive CSF using the Ward method. The proportions of patients with JCV-positive CSF and the detection rate of JCV in the specimens in each group were compared using the two-tailed Fisher&#8217;s exact test. The copy numbers of the detected JCVs in each group were statistically compared using the Wilcoxon test. All <italic toggle="yes">p</italic>-values &lt; 0.05 were considered statistically significant. The overall incidence rates and 95% confidence interval (CI) of PML cases were calculated based on general population estimates published by the Statistics Bureau of the Ministry of Internal Affairs and Communications of Japan [<xref rid="B79-viruses-15-00968" ref-type="bibr">79</xref>].</p></sec></sec><sec sec-type="results" id="sec3-viruses-15-00968"><title>3. Results</title><sec id="sec3dot1-viruses-15-00968"><title>3.1. Long-Term Performance of Laboratory Surveillance of PML Using PCR Testing for JCV in the CSF</title><p>First, we evaluated the performance of the nationwide laboratory surveillance for PML based on PCR testing for JCV in the CSF, which has been ongoing since FY2007. PCR examinations of 2594 specimens, including follow-up tests, were conducted up to FY2020. The number of tests gradually increased from FY2007 to FY2010, which was the start-up period that was previously reported [<xref rid="B72-viruses-15-00968" ref-type="bibr">72</xref>]. From FY2011 to FY2020, which was our study period, we observed that 177&#8211;254 tests were conducted annually, except for FY2016 (<xref rid="viruses-15-00968-f001" ref-type="fig">Figure 1</xref>A). During the start-up period (FY2007&#8211;2010), new requests for JCV testing were frequently made through the website; however, in subsequent periods of this study, 60%&#8211;80% of the requests came from the departments of medical institutions that had previously performed testing (<xref rid="viruses-15-00968-f001" ref-type="fig">Figure 1</xref>B). More than 70% of the physicians who requested CSF-JCV testing were from the department of neurology, while only a small percentage of requests were received from other departments (<xref rid="viruses-15-00968-f001" ref-type="fig">Figure 1</xref>C). The number of newly tested individuals reached a peak in FY2014 and declined through FY2016, when the real-time PCR testing for JCV in the CSF became widely available in commercial laboratories. Since then, the number has recovered to approximately 150 annually (<xref rid="viruses-15-00968-f001" ref-type="fig">Figure 1</xref>D). From FY2007 to FY2018, the number of new patients with JCV-positive CSF has been increasing, with at least 30 patients identified annually over the past 5 years (<xref rid="viruses-15-00968-f001" ref-type="fig">Figure 1</xref>E). The percentage of patients with JCV-positive CSF among newly tested patients remained between 10% and 15% from FY2007 to FY2015 but increased sharply in FY2016 and remained high (<xref rid="viruses-15-00968-f001" ref-type="fig">Figure 1</xref>F). These results indicate that the CSF-JCV testing at the NIID was widely recognized during the study period (FY2011&#8211;2020), particularly by neurologists, and that the frequency of identifying patients with JCV-positive CSF has been increasing since FY2016.</p></sec><sec id="sec3dot2-viruses-15-00968"><title>3.2. Geographic Distribution of the Study Population and Patients with JCV-Positive CSF</title><p>During the study period (FY2011&#8211;2020), CSF-JCV testing was requested by physicians at hospitals in all 47 prefectures of Japan for 1537 new cases suspected of having PML (<xref rid="viruses-15-00968-f002" ref-type="fig">Figure 2</xref>A). The number of requests for CSF-JCV testing showed a pattern similar to the distribution of the Japanese population, with more requests (&#8805;80 cases) received from urban areas, such as Tokyo, Osaka, Kanagawa, Aichi, and Hokkaido (especially Sapporo City). Of these cases, 288 patients (18.7%) had JCV-positive CSF. The geographic distribution of individuals with JCV-positive CSF showed a similar pattern to that of the study population (<xref rid="viruses-15-00968-f002" ref-type="fig">Figure 2</xref>B), and a statistical correlation was found between the two groups (Spearman&#8217;s rank correlation coefficient: 0.760, <italic toggle="yes">p</italic> &lt; 0.001). Hierarchical cluster analysis of the percentage of patients with JCV-positive CSF in each prefecture revealed five clusters (<xref rid="viruses-15-00968-f002" ref-type="fig">Figure 2</xref>C). Plotting the trends of these clusters on a map of Japan revealed higher percentages of positive cases in northern coastal prefectures (<xref rid="viruses-15-00968-f002" ref-type="fig">Figure 2</xref>D). Among these clusters, the prefecture with the highest positivity rate (cluster 1) was Akita. The prefectures in cluster 2 were, from east to west, Hokkaido, Niigata, Toyama, Mie, Shimane, Yamaguchi, Saga, Nagasaki, and Okinawa. Major metropolitan areas with a large number of subjects, the Tokyo, Osaka, Kanagawa, and Aichi prefectures were classified as clusters 3 or 4, with relatively low positivity rates. These results suggest that the number of patients with PML correlates with the number of suspected cases, and that the proportion of positive cases is unevenly distributed among regions in Japan.</p></sec><sec id="sec3dot3-viruses-15-00968"><title>3.3. Overview of Patients with JCV-Positive CSF</title><p>During the study period (FY2011&#8211;2020), patients with JCV-positive CSF were grouped based on their underlying conditions (<xref rid="viruses-15-00968-f003" ref-type="fig">Figure 3</xref>). Of the 288 positive patients, 19.8% had HIV infection/acquired immunodeficiency syndrome (AIDS), and 43.9% of them were already receiving combined antiretroviral therapy. Additionally, 27.1% and 26.0% of patients with JCV-positive CSF experienced hematological and autoimmune disorders, respectively. The proportions of patients with JCV-positive CSF with a history of solid-organ transplantation, solid tumors, and other diseases accounted for 4.2%, 2.8%, and 13.9%, respectively. Moreover, 6.3% of the patients had no clinically apparent underlying disease identified by their treating physicians despite having JCV-positive CSF. The age and sex distributions of the patients with JCV-positive CSF are shown in <xref rid="viruses-15-00968-f004" ref-type="fig">Figure 4</xref>. When all 288 positive cases were combined, the age range was broadly distributed, with peaks in the 60s, and median ages of 60.5 and 65.0 years for males and females, respectively (<xref rid="viruses-15-00968-f004" ref-type="fig">Figure 4</xref>A). Although there was a higher proportion of males in patients up to their 40s, the male-to-female ratio among all patients with JCV-positive CSF was nearly equal at 1.1 to 1 (152 male patients). However, when the categories of underlying conditions separated the distribution, the majority of individuals with JCV-positive CSF were males in their 30s and 40s for HIV infection (<xref rid="viruses-15-00968-f004" ref-type="fig">Figure 4</xref>B), males and females in their 60s and 70s for hematological disorders (<xref rid="viruses-15-00968-f004" ref-type="fig">Figure 4</xref>C), females in their 50s to 70s for autoimmune disorders (<xref rid="viruses-15-00968-f004" ref-type="fig">Figure 4</xref>D), and males and females in their 60s for other diseases (<xref rid="viruses-15-00968-f004" ref-type="fig">Figure 4</xref>E). Individuals with JCV-positive CSF in the absence of a clinically recognizable underlying disease as a risk factor for PML were primarily males and females in their 80s (<xref rid="viruses-15-00968-f004" ref-type="fig">Figure 4</xref>F). The age distribution and sex ratio patterns of patients with JCV-positive CSF were similar to those of the tested population (<xref rid="app1-viruses-15-00968" ref-type="app">Supplementary Figure S1</xref>). These results suggest that PML occurs with various predisposing factors in Japan, and its characteristics differ according to the categories of underlying conditions.</p></sec><sec id="sec3dot4-viruses-15-00968"><title>3.4. Categories of Underlying Conditions of Patients with JCV-Positive CSF</title><p>To evaluate the risk of PML in the study population with different underlying conditions, laboratory surveillance was conducted to collect standardized clinical information for suspected cases, regardless of the CSF-JCV test results. The next set of analyses aimed to determine the JCV detection rate in the CSF (in the study population) and the types of underlying diseases. From FY2011&#8211;2020, the proportion of patients with JCV-positive CSF in each category ranged from 22.7% to 27.1%, except for those with solid tumors (8.9%) and those without apparent underlying diseases (4.7%) (<xref rid="viruses-15-00968-t001" ref-type="table">Table 1</xref>). Notably, the percentages of patients with JCV-positive CSF in various underlying disease categories, excluding those with organ transplantation history or solid tumors, were significantly higher in the second 5 years (FY2016&#8211;2020), when ultrasensitive PCR testing was implemented, compared with the first 5 years (FY2011&#8211;2015), when standard PCR testing was used. The overall incidence rates of laboratory-identified PML per 100,000 person-years in the first (FY2011&#8211;2015) and second (FY2016&#8211;2020) periods were 0.016 (95% CI, 0.013&#8211;0.020) and 0.029 (95% CI, 0.025&#8211;0.034), respectively. These results suggest that PML was more effectively diagnosed in clinical practice during the second 5 years than the first 5 years.</p></sec><sec id="sec3dot5-viruses-15-00968"><title>3.5. Patients with JCV-Positive CSF and Hematological Disorders</title><p><xref rid="viruses-15-00968-t002" ref-type="table">Table 2</xref> displays the percentages of patients with JCV-positive CSF and the types of hematological disorders identified during the study period. JCV was found in 78 out of 305 patients, spanning a wide range of 25 disease types. For each disease type, the number of patients was small, and no statistically significant differences in the proportion of patients with JCV-positive CSF were demonstrated between the first (FY2011&#8211;2015) and second (FY2016&#8211;2020) periods. During the study period FY2011&#8211;2020, 19.2% of patients with JCV-positive CSF had diffuse large B-cell lymphoma (DLBCL). Patients with various types of non-Hodgkin lymphoma, including DLBCL, accounted for 53.8% (42/78) of patients with JCV-positive CSF in this category. JCV was also detected in the CSF of patients with multiple myeloma, leukemia, and other hematological diseases. Although the number of patients with JCV-positive CSF was small, the positivity rates exceeded 40% for patients with 13 of 25 (52%) diseases. These findings suggest that various hematological disorders predispose Japanese patients to PML, and that more than half of the patients with PML in this category had non-Hodgkin lymphoma.</p></sec><sec id="sec3dot6-viruses-15-00968"><title>3.6. Patients with JCV-Positive CSF and Autoimmune Disorders</title><p>The proportions of patients with JCV-positive CSF and autoimmune disorders (75/331 patients) and their disease types are shown in <xref rid="viruses-15-00968-t003" ref-type="table">Table 3</xref>. In this category, JCV was detected in the CSF samples of patients with 15 different diseases. When comparing the first half (FY2011&#8211;2015) to the second half (FY2016&#8211;2020) of the study period, no statistically significant difference was found in the percentage of patients with JCV-positive CSF for each disease type. However, the number of patients with JCV-positive CSF in the second period was higher than that in the first period among patients with major PML-predisposing diseases, such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and MS. Of the patients with JCV-positive CSF during the study period FY2011&#8211;2020, 45.3% and 13.3% had SLE and RA, respectively. CSF-JCV-positive cases for other disease types were sporadic, accounting for &lt;10% each in this category. However, the positivity rates of CSF-JCV for the entire period were &#8805;50% for 6 of the 13 diseases. In addition, patients with JCV-positive CSF and several autoimmune diseases were found to have various complications. Data for these cases are summarized in <xref rid="viruses-15-00968-t004" ref-type="table">Table 4</xref>. With the exception of patients with MS and microscopic polyangiitis, individuals with JCV-positive CSF and autoimmune disorders were identified both with and without complications. These findings suggest that SLE is the predominant type of autoimmune disease underlying PML in Japan, and that PML may develop with or without complications.</p></sec><sec id="sec3dot7-viruses-15-00968"><title>3.7. Patients with JCV-Positive CSF and Other Underlying Diseases</title><p>The percentages and underlying conditions of patients with JCV-positive CSF and a history of organ transplantation, solid tumors, and other diseases (60/308 patients) are listed in <xref rid="viruses-15-00968-t005" ref-type="table">Table 5</xref>. Owing to the small number of patients in each group, pooled data are tabulated for the entire period. In patients with a history of organ transplantation, 75% of the patients with JCV-positive CSF had received kidney transplantation, indicating a high positivity rate of 28.1% in the tested population. In patients with JCV-positive CSF and solid tumors, the lesions were found in various organs without a distinct pattern. In the groups with the remaining background diseases, 40 patients with JCV-positive CSF were identified. Of these, 16 (40%) had chronic kidney disease, mainly renal failure, whereas patients with JCV-positive CSF and with lung, hepatic, or infectious diseases were rare. In patients with primary immunodeficiency syndromes, the number of patients with JCV-positive CSF was small (<italic toggle="yes">n</italic> = 6). However, all patients with Good syndrome or combined immunodeficiency had JCV-positive CSF. In the group having other diseases, seven patients with sarcoidosis were JCV-positive in the CSF. The positivity rate of JCV in the CSF among patients with sarcoidosis was as high as 46.7%. These results suggest that kidney transplantation, chronic kidney disease, primary immunodeficiency syndrome, and sarcoidosis as well as HIV infection, hematological disorders, and autoimmune disorders are PML-predisposing factors in Japan.</p></sec><sec id="sec3dot8-viruses-15-00968"><title>3.8. Copy Numbers of JCV in the CSF</title><p>The final set of analyses aimed to examine the JCV copy numbers in the CSF during the initial PCR testing of positive cases. The JCV loads in the CSF specimens were widely distributed with a median value of 6.4 &#215; 10<sup>4</sup> copies/mL during the first 5 years (FY2011&#8211;2015), when the standard PCR testing was implemented (<xref rid="viruses-15-00968-f005" ref-type="fig">Figure 5</xref>A, left). During this period, the median JCV levels in patients with HIV infection, hematological disorders, autoimmune disorders, and other diseases were 2.8 &#215; 10<sup>5</sup>, 2.0 &#215; 10<sup>5</sup>, 1.2 &#215; 10<sup>4</sup>, and 1.2 &#215; 10<sup>4</sup> copies/mL, respectively (<xref rid="viruses-15-00968-f005" ref-type="fig">Figure 5</xref>B&#8211;E, left). A broad distribution of JCV copies was also observed during the second 5 years (FY2016&#8211;2020), when ultrasensitive PCR testing was introduced (<xref rid="viruses-15-00968-f005" ref-type="fig">Figure 5</xref>A, right). However, the median JCV load in the second period was 2.2 &#215; 10<sup>3</sup> copies/mL, with a significant number of cases (<italic toggle="yes">n</italic> = 36/186; 19.4%) having low JCV loads of &lt;200 copies/mL. The median JCV copy numbers were in the same order of magnitude (from 1.5 &#215; 10<sup>3</sup> to 4.0 &#215; 10<sup>3</sup> copies/mL) in each underlying disease group during the second study period (<xref rid="viruses-15-00968-f005" ref-type="fig">Figure 5</xref>B&#8211;F, right). For the total population and groups with HIV infection, hematological disorders, and autoimmune disorders, the JCV levels in the CSF in the second period were statistically significantly lower than those in the first period (<xref rid="viruses-15-00968-f005" ref-type="fig">Figure 5</xref>A&#8211;D). These findings suggest that physicians had a better understanding of the risk of PML during the second period, and the ultrasensitive PCR testing in the early stage of the disease detected fewer copy ranges of JCV in the CSF.</p></sec></sec><sec sec-type="discussion" id="sec4-viruses-15-00968"><title>4. Discussion</title><p>In this study, we conducted nationwide laboratory surveillance in Japan for 10 years to analyze the overall picture of PML, a rare disease for which reporting is often not mandatory, except for adverse drug events; thus, assessing its incidence trends in real time is difficult. The ongoing laboratory surveillance in Japan is based on a strategy to identify patients suspected of having PML and predisposing conditions by consolidating CSF-JCV testing in a national laboratory (NIID). However, during the initial four-year start-up period (FY2007&#8211;2010), it was difficult to assert that this system had become widespread throughout Japan, mainly due to the simultaneous web-based notification and implementation of CSF-JCV testing at the NIID. Nevertheless, over the next decade, there was an increase in repeat requests from hospital departments with a history of CSF-JCV testing at the NIID, promoting more stable surveillance. In a nationwide population-based cohort study using a public database, the incidence rate of 0.11 per 100,000 person-years was reported for PML in France from 2010 to 2017 [<xref rid="B58-viruses-15-00968" ref-type="bibr">58</xref>]. In this study, the incidence rate of PML in Japan was 0.029 per 100,000 person-years, even with an improved surveillance system during the last five years (FY2016&#8211;2020). This relatively low incidence of PML in Japan may be attributed to patients with PML who were not tested at the NIID or cases where CSF-JCV could not be detected despite PML development. Alternatively, the relatively small number of individuals with major predisposing factors for PML, such as HIV infection and MS, may account for the low incidence of PML in Japan, as described below.</p><p>The hierarchical cluster analysis showed that prefectures with higher CSF-JCV-positive rates among the tested population were mainly distributed along the northern coasts facing the Sea of Japan. However, the reasons for this trend are unknown and require further analysis. Although facilities capable of providing advanced medical care have been established in every prefecture in Japan, the number of hospitals and the frequency of neurology departments tend to be higher in metropolitan areas. Therefore, it is difficult to believe that the level of medical care in neurology is directly reflected in the positivity rate. As JCV is widespread among healthy individuals [<xref rid="B15-viruses-15-00968" ref-type="bibr">15</xref>], the regional bias in the infection rate of this virus will unlikely reflect the positivity for JCV in the CSF. Although several sub-lineages of JCV archetypes are circulating in Japan [<xref rid="B15-viruses-15-00968" ref-type="bibr">15</xref>], no significant difference in the reactivation or pathogenicity of these viruses was found. Contrastingly, it is difficult to say that many patients with underlying PML-predisposing diseases are found in prefectures with a high CSF-JCV-positivity rate. Compared with other regions (clusters 3&#8211;5), the positive rates in these regions (clusters 1 and 2) were statistically significantly higher in patients with HIV infection, hematological disorders, and other diseases (<xref rid="app1-viruses-15-00968" ref-type="app">Supplementary Table S1</xref>). However, the regions with the highest number of people with HIV infection in Japan are metropolitan areas, such as Tokyo, Osaka, and Fukuoka [<xref rid="B80-viruses-15-00968" ref-type="bibr">80</xref>], which do not include prefectures with high positive rates for CSF-JCV.</p><p>As different underlying conditions and therapeutic interventions predispose patients to PML development, the incidence of PML is likely to vary between countries. Therefore, a detailed list of these predisposing factors and the proportion of patients with PML among suspected cases could aid in clinical management. The age group and sex patterns of the individuals tested and those with JCV-positive CSF in each disease category were comparable, suggesting that the characteristics of predisposing conditions are reflected in PML development. In contrast to the United States and France, where nearly half of PML cases are associated with HIV infection [<xref rid="B2-viruses-15-00968" ref-type="bibr">2</xref>,<xref rid="B58-viruses-15-00968" ref-type="bibr">58</xref>,<xref rid="B81-viruses-15-00968" ref-type="bibr">81</xref>], the proportion of HIV-associated PML cases in Japan is low, approximately 20%, as revealed in this study. The relatively low rate of HIV-associated PML in Japan is consistent with the low prevalence of HIV infection in this country [<xref rid="B82-viruses-15-00968" ref-type="bibr">82</xref>].</p><p>After the start-up period (FY2007&#8211;2010) [<xref rid="B72-viruses-15-00968" ref-type="bibr">72</xref>], numerous patients with JCV-positive CSF were found in the group with hematological disorders during the 10-year study period. More than half of the patients with JCV-positive CSF in this group had non-Hodgkin lymphoma. However, other very diverse predisposing factors were also implicated in PML. In addition, the literature search did not identify any case reports of PML associated with essential thrombocythemia or thyroid lymphoma. The data in this study indicate no statistically significant increase in the incidence of PML in the first (FY2011&#8211;2015) and second (FY2016&#8211;2020) study periods among patients with hematological disorders, partly because of the small number of patients with JCV-positive CSF who had each disease. However, one patient with JCV-positive CSF had multiple myeloma in the first period, compared with eight in the second period, suggesting that PML may increase or continue to occur in Japan over time in the context of multiple myeloma. However, a more detailed analysis of PML in the context of hematologic diseases, including treatment history, is needed.</p><p>In contrast to the 4-year start-up period, during which only three patients with JCV-positive CSF were found to have autoimmune disorders [<xref rid="B72-viruses-15-00968" ref-type="bibr">72</xref>], 75 patients with JCV-positive CSF were identified in this underlying disease category during the 10-year study period. The reasons for the recent increase in identified PML cases with autoimmune disorders are not fully understood. Approximately 45% of patients with JCV-positive CSF in the autoimmune disease group had SLE, and no major changes, such as the introduction of newly developed drugs, have been observed in managing this disease. Furthermore, although there has been a rise in fingolimod-associated PML cases [<xref rid="B83-viruses-15-00968" ref-type="bibr">83</xref>], the number of patients with JCV-positive CSF receiving disease-modifying therapy (DMT) for MS was not very high, with an underlying disease rate of &lt;10% in this category. This observation could reflect the low prevalence of MS and the delayed introduction of new treatments in Japan compared with the United States and Europe [<xref rid="B84-viruses-15-00968" ref-type="bibr">84</xref>]. Thus, while DMT-associated PML is a serious concern, it is unlikely to be directly responsible for the significant increase in PML cases with autoimmune disorders in Japan. Nevertheless, increased awareness of DMT-associated PML may have led to a recognition of the importance of considering PML in patients with various autoimmune disorders in Japan. Furthermore, a PubMed search did not reveal any case reports of PML in patients with underlying diseases such as eosinophilic granulomatosis with polyangiitis (previously known as Churg&#8211;Strauss syndrome), pemphigus foliaceus, polymyalgia rheumatica, or myelin oligodendrocyte glycoprotein antibody-associated disease. PML surveillance is important from a pharmacovigilance perspective because the use of newly developed drugs and the expansion of indications for existing agents are not uncommon in the treatment of autoimmune diseases.</p><p>In this study, laboratory surveillance identified 16 patients with JCV-positive CSF who had chronic kidney disease. In addition, cases of PML in renal failure have been reported [<xref rid="B85-viruses-15-00968" ref-type="bibr">85</xref>]. Notably, a non-negligible number of patients with JCV-positive CSF at various stages of chronic kidney disease were observed in this study. Thus, these data demonstrate that chronic kidney disease is a predisposing factor for PML in Japan. In addition, PML rarely occurs in patients with no apparent underlying diseases or with minimal immunosuppression [<xref rid="B70-viruses-15-00968" ref-type="bibr">70</xref>,<xref rid="B85-viruses-15-00968" ref-type="bibr">85</xref>,<xref rid="B86-viruses-15-00968" ref-type="bibr">86</xref>]. Sriwastava et al. conducted a thorough review of the literature on PML in immunocompetent patients and identified 21 published case reports to date, in addition to their own case, with a median patient age of 60 years (range 29&#8211;83, SD = 14.0) [<xref rid="B70-viruses-15-00968" ref-type="bibr">70</xref>]. In this study, laboratory surveillance identified 18 patients with JCV-positive CSF who had no clinically apparent underlying disease in only one country. Approximately 89% of these patients were seen during the second study period, when ultrasensitive testing was introduced. The patients with JCV-positive CSF had a median age of 77.5 years (range 50&#8211;89, SD = 10.3), suggesting that older age may be a predisposing factor for PML in Japan. The exact pathogenesis of PML associated with aging is currently unclear. Although these patients have not been extensively analyzed and have not been clinically diagnosed with an underlying condition, such as idiopathic CD4-positive T lymphocytopenia, it is possible that their T-cell immunity may be compromised due to aging, which could lead to PML. Japan has one of the highest life expectancies globally [<xref rid="B87-viruses-15-00968" ref-type="bibr">87</xref>], and it is important to increase clinical awareness of PML among older individuals.</p><p>In the second study period, the ultrasensitive PCR testing for JCV in the CSF was introduced into laboratory surveillance to address PML associated with DMT for MS, which often has low viral copy numbers in CSF samples [<xref rid="B88-viruses-15-00968" ref-type="bibr">88</xref>]. This large-scale study demonstrated that ultrasensitive JCV testing contributes to PML diagnosis in patients with various predisposing factors and DMT. However, the marked increase in the percentage of CSF-JCV-positive cases among participants in FY2016 and beyond must take into account the increased attention given to PML by physicians in clinical practice in Japan. Additionally, the positivity rates for JCV in the CSF may have been influenced by standard real-time PCR testing in commercial laboratories, which became widespread during this period, as well as ultrasensitive JCV testing. Essentially, the number of patients tested in FY2016 decreased, followed by an increase in the number of patients with JCV-positive CSF. The commercial JCV tests likely screened a larger population, followed by the requests for ultrasensitive JCV testing at the NIID for confirmation and follow-up, resulting in an increase in the number of identifiable PML cases.</p><p>Apart from the diagnosis based on pathological findings of brain tissue, PML is clinically diagnosed based on the patient&#8217;s neurological symptoms and MRI findings as well as the detection of JCV in the CSF [<xref rid="B71-viruses-15-00968" ref-type="bibr">71</xref>]. According to information provided by the physician during follow-up testing, nearly all patients with JCV-positive CSF at the NIID were diagnosed with PML. However, in other cases, no follow-up testing was performed at the NIID after a positive result, and no additional clinical information is available as to whether individuals with JCV-positive CSF were diagnosed with PML or not. While laboratory surveillance using CSF-JCV testing can be the first line for detecting PML and suspected cases, analyzing detailed clinical presentations and MRI data, tracking prognosis over time, and comparing test results performed at a later date in other laboratories are challenging. For these reasons, with the patient&#8217;s consent, individuals suspected of PML who have undergone CSF-JCV testing at the NIID are registered in the Research Committee of Prion Disease and Slow Virus Infection, regardless of the PCR results. A multifaceted and integrated analysis of suspected PML cases is then performed by a research team consisting of neurologists, radiologists, pathologists, epidemiologists, and virologists in Japan. The findings of this analysis will be published in the future and will serve as a crucial source of information for PML diagnosis and management.</p></sec><sec sec-type="conclusions" id="sec5-viruses-15-00968"><title>5. Conclusions</title><p>Nationwide laboratory surveillance using PCR testing for JCV in CSF samples over the past decade has provided valuable insights into the overall profile of PML in Japan. The data analyzed in this study will not only aid in the diagnosis of PML, but also in understanding the risk of PML associated with underlying diseases and informing their treatment.</p></sec></body><back><ack><title>Acknowledgments</title><p>We would like to express our deep appreciation to all the study participants and physicians who contributed to this study. We are also grateful to Rumiko Takaura for her thoughtful assistance with PML surveillance at the national level.</p></ack><fn-group><fn><p><bold>Disclaimer/Publisher&#8217;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><app-group><app id="app1-viruses-15-00968"><title>Supplementary Materials</title><p>The following supporting information can be downloaded at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.mdpi.com/article/10.3390/v15040968/s1">https://www.mdpi.com/article/10.3390/v15040968/s1</uri>, Figure S1: Age and sex distribution patterns of the study population; Table S1: Underlying disease categories of patients and detection rates of CSF JCV in areas with a high proportion of positive cases.</p><supplementary-material id="viruses-15-00968-s001" position="float" content-type="local-data" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="viruses-15-00968-s001.zip" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>Conceptualization, K.N. (Kazuo Nakamichi), H.M. and M.S.; methodology, K.N. (Kazuo Nakamichi), S.N. and M.S.; software, K.N. (Kazuo Nakamichi) and T.S. (Toshio Shimokawa); validation, K.N. (Kazuo Nakamichi) and T.S. (Toshio Shimokawa); formal analysis, K.N. (Kazuo Nakamichi) and T.S. (Toshio Shimokawa); investigation, K.N. (Kazuo Nakamichi), Y.M., T.S. (Toshio Shimokawa), K.T. (Kenta Takahashi) and T.S. (Tadaki Suzuki); resources, K.N. (Kazuo Nakamichi) and H.E.; data curation, K.N. (Kazuo Nakamichi) and Y.M.; writing&#8212;original draft preparation, K.N. (Kazuo Nakamichi); writing&#8212;review and editing, K.N. (Kazuo Nakamichi), Y.M., T.S. (Toshio Shimokawa), K.T. (Kenta Takahashi), T.S. (Tadaki Suzuki), N.F., M.H., K.M., N.S., M.Y. (Motohiro Yukitake), K.T. (Kazuya Takahashi), T.H., S.I., S.O., J.N., R.A., K.K., S.N., Y.N., K.N. (Kyoichi Nomura), S.K., H.M., M.Y. (Masahito Yamada), M.T., H.E. and M.S.; visualization, K.N. (Kazuo Nakamichi) and T.S. (Toshio Shimokawa); supervision, K.N. (Kazuo Nakamichi), H.M., M.Y. (Masahito Yamada), M.T. and M.S.; project administration, K.N. (Kazuo Nakamichi); funding acquisition, K.N. (Kazuo Nakamichi), T.H., H.M. (Masahito Yamada), M.T. and M.S. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>The study was conducted in accordance with the Declaration of Helsinki and was approved by the Institutional Review Board of the NIID (approval nos. 1248 and 1317).</p></notes><notes><title>Informed Consent Statement</title><p>Informed consent was obtained from all subjects involved in the study.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>The analyzed datasets are available in the article and its <xref rid="app1-viruses-15-00968" ref-type="app">Supplementary Materials</xref>, or are available from the corresponding author upon reasonable request.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><ref-list><title>References</title><ref id="B1-viruses-15-00968"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Major</surname><given-names>E.O.</given-names></name><name name-style="western"><surname>Yousry</surname><given-names>T.A.</given-names></name><name name-style="western"><surname>Clifford</surname><given-names>D.B.</given-names></name></person-group><article-title>Pathogenesis of Progressive Multifocal Leukoencephalopathy and Risks Associated with Treatments for Multiple Sclerosis: A Decade of Lessons Learned</article-title><source>Lancet Neurol.</source><year>2018</year><volume>17</volume><fpage>467</fpage><lpage>480</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(18)30040-1</pub-id><pub-id pub-id-type="pmid">29656742</pub-id></element-citation></ref><ref id="B2-viruses-15-00968"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cortese</surname><given-names>I.</given-names></name><name name-style="western"><surname>Reich</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Nath</surname><given-names>A.</given-names></name></person-group><article-title>Progressive Multifocal Leukoencephalopathy and the Spectrum of JC Virus-Related Disease</article-title><source>Nat. Rev. Neurol.</source><year>2021</year><volume>17</volume><fpage>37</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1038/s41582-020-00427-y</pub-id><pub-id pub-id-type="pmid">33219338</pub-id><pub-id pub-id-type="pmcid">PMC7678594</pub-id></element-citation></ref><ref id="B3-viruses-15-00968"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pavlovic</surname><given-names>D.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Patera</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Peterson</surname><given-names>I.</given-names></name></person-group><article-title>Progressive Multifocal Leukoencephalopathy Consortium. T Cell Deficiencies as a Common Risk Factor for Drug Associated Progressive Multifocal Leukoencephalopathy</article-title><source>Immunobiology</source><year>2018</year><volume>223</volume><fpage>508</fpage><lpage>517</lpage><pub-id pub-id-type="doi">10.1016/j.imbio.2018.01.002</pub-id><pub-id pub-id-type="pmid">29472141</pub-id></element-citation></ref><ref id="B4-viruses-15-00968"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shishido-Hara</surname><given-names>Y.</given-names></name></person-group><article-title>Progressive Multifocal Leukoencephalopathy and Promyelocytic Leukemia Nuclear Bodies: A Review of Clinical, Neuropathological, and Virological Aspects of JC Virus-Induced Demyelinating Disease</article-title><source>Acta Neuropathol.</source><year>2010</year><volume>120</volume><fpage>403</fpage><lpage>417</lpage><pub-id pub-id-type="doi">10.1007/s00401-010-0694-x</pub-id><pub-id pub-id-type="pmid">20464404</pub-id><pub-id pub-id-type="pmcid">PMC2910879</pub-id></element-citation></ref><ref id="B5-viruses-15-00968"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Walker</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Siddell</surname><given-names>S.G.</given-names></name><name name-style="western"><surname>Lefkowitz</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Mushegian</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Adriaenssens</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Alfenas-Zerbini</surname><given-names>P.</given-names></name><name name-style="western"><surname>Dempsey</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Dutilh</surname><given-names>B.E.</given-names></name><name name-style="western"><surname>Garc&#237;a</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Curtis Hendrickson</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Recent Changes to Virus Taxonomy Ratified by the International Committee on Taxonomy of Viruses (2022)</article-title><source>Arch. Virol.</source><year>2022</year><volume>167</volume><fpage>2429</fpage><lpage>2440</lpage><pub-id pub-id-type="doi">10.1007/s00705-022-05516-5</pub-id><pub-id pub-id-type="pmid">35999326</pub-id><pub-id pub-id-type="pmcid">PMC10088433</pub-id></element-citation></ref><ref id="B6-viruses-15-00968"><label>6.</label><element-citation publication-type="webpage"><article-title>ICTV Genus: Betapolyomavirus | ICTV</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://ictv.global/report/chapter/polyomaviridae/polyomaviridae/betapolyomavirus" ext-link-type="uri">https://ictv.global/report/chapter/polyomaviridae/polyomaviridae/betapolyomavirus</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-03-03">(accessed on 3 March 2023)</date-in-citation></element-citation></ref><ref id="B7-viruses-15-00968"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>D&#246;rries</surname><given-names>K.</given-names></name></person-group><article-title>Molecular Biology and Pathogenesis of Human Polyomavirus Infections</article-title><source>Dev. Biol. Stand.</source><year>1998</year><volume>94</volume><fpage>71</fpage><lpage>79</lpage><pub-id pub-id-type="pmid">9776228</pub-id></element-citation></ref><ref id="B8-viruses-15-00968"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zheng</surname><given-names>H.-Y.</given-names></name><name name-style="western"><surname>Kitamura</surname><given-names>T.</given-names></name><name name-style="western"><surname>Takasaka</surname><given-names>T.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Yogo</surname><given-names>Y.</given-names></name></person-group><article-title>Unambiguous Identification of JC Polyomavirus Strains Transmitted from Parents to Children</article-title><source>Arch. Virol.</source><year>2004</year><volume>149</volume><fpage>261</fpage><lpage>273</lpage><pub-id pub-id-type="doi">10.1007/s00705-003-0214-6</pub-id><pub-id pub-id-type="pmid">14745594</pub-id></element-citation></ref><ref id="B9-viruses-15-00968"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ferenczy</surname><given-names>M.W.</given-names></name><name name-style="western"><surname>Marshall</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Nelson</surname><given-names>C.D.S.</given-names></name><name name-style="western"><surname>Atwood</surname><given-names>W.J.</given-names></name><name name-style="western"><surname>Nath</surname><given-names>A.</given-names></name><name name-style="western"><surname>Khalili</surname><given-names>K.</given-names></name><name name-style="western"><surname>Major</surname><given-names>E.O.</given-names></name></person-group><article-title>Molecular Biology, Epidemiology, and Pathogenesis of Progressive Multifocal Leukoencephalopathy, the JC Virus-Induced Demyelinating Disease of the Human Brain</article-title><source>Clin. Microbiol. Rev.</source><year>2012</year><volume>25</volume><fpage>471</fpage><lpage>506</lpage><pub-id pub-id-type="doi">10.1128/CMR.05031-11</pub-id><pub-id pub-id-type="pmid">22763635</pub-id><pub-id pub-id-type="pmcid">PMC3416490</pub-id></element-citation></ref><ref id="B10-viruses-15-00968"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Monaco</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Atwood</surname><given-names>W.J.</given-names></name><name name-style="western"><surname>Gravell</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tornatore</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Major</surname><given-names>E.O.</given-names></name></person-group><article-title>JC Virus Infection of Hematopoietic Progenitor Cells, Primary B Lymphocytes, and Tonsillar Stromal Cells: Implications for Viral Latency</article-title><source>J. Virol.</source><year>1996</year><volume>70</volume><fpage>7004</fpage><lpage>7012</lpage><pub-id pub-id-type="doi">10.1128/jvi.70.10.7004-7012.1996</pub-id><pub-id pub-id-type="pmid">8794345</pub-id><pub-id pub-id-type="pmcid">PMC190751</pub-id></element-citation></ref><ref id="B11-viruses-15-00968"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marzocchetti</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wuthrich</surname><given-names>C.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Tompkins</surname><given-names>T.</given-names></name><name name-style="western"><surname>Bernal-Cano</surname><given-names>F.</given-names></name><name name-style="western"><surname>Bhargava</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ropper</surname><given-names>A.H.</given-names></name><name name-style="western"><surname>Koralnik</surname><given-names>I.J.</given-names></name></person-group><article-title>Rearrangement of the JC Virus Regulatory Region Sequence in the Bone Marrow of a Patient with Rheumatoid Arthritis and Progressive Multifocal Leukoencephalopathy</article-title><source>J. Neurovirol.</source><year>2008</year><volume>14</volume><fpage>455</fpage><lpage>458</lpage><pub-id pub-id-type="doi">10.1080/13550280802356837</pub-id><pub-id pub-id-type="pmid">18989816</pub-id><pub-id pub-id-type="pmcid">PMC2643300</pub-id></element-citation></ref><ref id="B12-viruses-15-00968"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tan</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Dezube</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Bhargava</surname><given-names>P.</given-names></name><name name-style="western"><surname>Autissier</surname><given-names>P.</given-names></name><name name-style="western"><surname>W&#252;thrich</surname><given-names>C.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>J.</given-names></name><name name-style="western"><surname>Koralnik</surname><given-names>I.J.</given-names></name></person-group><article-title>Detection of JC Virus DNA and Proteins in the Bone Marrow of HIV-Positive and HIV-Negative Patients: Implications for Viral Latency and Neurotropic Transformation</article-title><source>J. Infect. Dis.</source><year>2009</year><volume>199</volume><fpage>881</fpage><lpage>888</lpage><pub-id pub-id-type="doi">10.1086/597117</pub-id><pub-id pub-id-type="pmid">19434914</pub-id><pub-id pub-id-type="pmcid">PMC2893283</pub-id></element-citation></ref><ref id="B13-viruses-15-00968"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Egli</surname><given-names>A.</given-names></name><name name-style="western"><surname>Infanti</surname><given-names>L.</given-names></name><name name-style="western"><surname>Dumoulin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Buser</surname><given-names>A.</given-names></name><name name-style="western"><surname>Samaridis</surname><given-names>J.</given-names></name><name name-style="western"><surname>Stebler</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gosert</surname><given-names>R.</given-names></name><name name-style="western"><surname>Hirsch</surname><given-names>H.H.</given-names></name></person-group><article-title>Prevalence of Polyomavirus BK and JC Infection and Replication in 400 Healthy Blood Donors</article-title><source>J. Infect. Dis.</source><year>2009</year><volume>199</volume><fpage>837</fpage><lpage>846</lpage><pub-id pub-id-type="doi">10.1086/597126</pub-id><pub-id pub-id-type="pmid">19434930</pub-id></element-citation></ref><ref id="B14-viruses-15-00968"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ault</surname><given-names>G.S.</given-names></name><name name-style="western"><surname>Stoner</surname><given-names>G.L.</given-names></name></person-group><article-title>Human Polyomavirus JC Promoter/Enhancer Rearrangement Patterns from Progressive Multifocal Leukoencephalopathy Brain Are Unique Derivatives of a Single Archetypal Structure</article-title><source>J. Gen. Virol.</source><year>1993</year><volume>74</volume><fpage>1499</fpage><lpage>1507</lpage><pub-id pub-id-type="doi">10.1099/0022-1317-74-8-1499</pub-id><pub-id pub-id-type="pmid">8393910</pub-id></element-citation></ref><ref id="B15-viruses-15-00968"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yogo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>S.</given-names></name><name name-style="western"><surname>Shibuya</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kitamura</surname><given-names>T.</given-names></name><name name-style="western"><surname>Homma</surname><given-names>Y.</given-names></name></person-group><article-title>Transcriptional Control Region Rearrangements Associated with the Evolution of JC Polyomavirus</article-title><source>Virology</source><year>2008</year><volume>380</volume><fpage>118</fpage><lpage>123</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2008.07.016</pub-id><pub-id pub-id-type="pmid">18718622</pub-id></element-citation></ref><ref id="B16-viruses-15-00968"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>White</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>Khalili</surname><given-names>K.</given-names></name></person-group><article-title>Pathogenesis of Progressive Multifocal Leukoencephalopathy-Revisited</article-title><source>J. Infect. Dis.</source><year>2011</year><volume>203</volume><fpage>578</fpage><lpage>586</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiq097</pub-id><pub-id pub-id-type="pmid">21227915</pub-id><pub-id pub-id-type="pmcid">PMC3072716</pub-id></element-citation></ref><ref id="B17-viruses-15-00968"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kleinschmidt-DeMasters</surname><given-names>B.K.</given-names></name><name name-style="western"><surname>Tyler</surname><given-names>K.L.</given-names></name></person-group><article-title>Progressive Multifocal Leukoencephalopathy Complicating Treatment with Natalizumab and Interferon Beta-1a for Multiple Sclerosis</article-title><source>N. Engl. J. Med.</source><year>2005</year><volume>353</volume><fpage>369</fpage><lpage>374</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa051782</pub-id><pub-id pub-id-type="pmid">15947079</pub-id></element-citation></ref><ref id="B18-viruses-15-00968"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Langer-Gould</surname><given-names>A.</given-names></name><name name-style="western"><surname>Atlas</surname><given-names>S.W.</given-names></name><name name-style="western"><surname>Green</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Bollen</surname><given-names>A.W.</given-names></name><name name-style="western"><surname>Pelletier</surname><given-names>D.</given-names></name></person-group><article-title>Progressive Multifocal Leukoencephalopathy in a Patient Treated with Natalizumab</article-title><source>N. Engl. J. Med.</source><year>2005</year><volume>353</volume><fpage>375</fpage><lpage>381</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa051847</pub-id><pub-id pub-id-type="pmid">15947078</pub-id></element-citation></ref><ref id="B19-viruses-15-00968"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Van Assche</surname><given-names>G.</given-names></name><name name-style="western"><surname>Van Ranst</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sciot</surname><given-names>R.</given-names></name><name name-style="western"><surname>Dubois</surname><given-names>B.</given-names></name><name name-style="western"><surname>Vermeire</surname><given-names>S.</given-names></name><name name-style="western"><surname>Noman</surname><given-names>M.</given-names></name><name name-style="western"><surname>Verbeeck</surname><given-names>J.</given-names></name><name name-style="western"><surname>Geboes</surname><given-names>K.</given-names></name><name name-style="western"><surname>Robberecht</surname><given-names>W.</given-names></name><name name-style="western"><surname>Rutgeerts</surname><given-names>P.</given-names></name></person-group><article-title>Progressive Multifocal Leukoencephalopathy after Natalizumab Therapy for Crohn&#8217;s Disease</article-title><source>N. Engl. J. Med.</source><year>2005</year><volume>353</volume><fpage>362</fpage><lpage>368</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa051586</pub-id><pub-id pub-id-type="pmid">15947080</pub-id></element-citation></ref><ref id="B20-viruses-15-00968"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sepp&#228;l&#228;</surname><given-names>H.</given-names></name><name name-style="western"><surname>Virtanen</surname><given-names>E.</given-names></name><name name-style="western"><surname>Saarela</surname><given-names>M.</given-names></name><name name-style="western"><surname>Laine</surname><given-names>P.</given-names></name><name name-style="western"><surname>Paul&#237;n</surname><given-names>L.</given-names></name><name name-style="western"><surname>Mannonen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Auvinen</surname><given-names>P.</given-names></name><name name-style="western"><surname>Auvinen</surname><given-names>E.</given-names></name></person-group><article-title>Single-Molecule Sequencing Revealing the Presence of Distinct JC Polyomavirus Populations in Patients with Progressive Multifocal Leukoencephalopathy</article-title><source>J. Infect. Dis.</source><year>2017</year><volume>215</volume><fpage>889</fpage><lpage>895</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiw399</pub-id><pub-id pub-id-type="pmid">28453853</pub-id></element-citation></ref><ref id="B21-viruses-15-00968"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ciardi</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Zingaropoli</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Iannetta</surname><given-names>M.</given-names></name><name name-style="western"><surname>Prezioso</surname><given-names>C.</given-names></name><name name-style="western"><surname>Perri</surname><given-names>V.</given-names></name><name name-style="western"><surname>Pasculli</surname><given-names>P.</given-names></name><name name-style="western"><surname>Lichtner</surname><given-names>M.</given-names></name><name name-style="western"><surname>d&#8217;Ettorre</surname><given-names>G.</given-names></name><name name-style="western"><surname>Altieri</surname><given-names>M.</given-names></name><name name-style="western"><surname>Conte</surname><given-names>A.</given-names></name><etal/></person-group><article-title>JCPyV NCCR Analysis in PML Patients with Different Risk Factors: Exploring Common Rearrangements as Essential Changes for Neuropathogenesis</article-title><source>Virol. J.</source><year>2020</year><volume>17</volume><fpage>23</fpage><pub-id pub-id-type="doi">10.1186/s12985-020-1295-5</pub-id><pub-id pub-id-type="pmid">32046748</pub-id><pub-id pub-id-type="pmcid">PMC7014659</pub-id></element-citation></ref><ref id="B22-viruses-15-00968"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nakamichi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Shimokawa</surname><given-names>T.</given-names></name></person-group><article-title>Database and Statistical Analyses of Transcription Factor Binding Sites in the Non-Coding Control Region of JC Virus</article-title><source>Viruses</source><year>2021</year><volume>13</volume><elocation-id>2314</elocation-id><pub-id pub-id-type="doi">10.3390/v13112314</pub-id><pub-id pub-id-type="pmid">34835120</pub-id><pub-id pub-id-type="pmcid">PMC8620444</pub-id></element-citation></ref><ref id="B23-viruses-15-00968"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wilczek</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Pike</surname><given-names>A.M.C.</given-names></name><name name-style="western"><surname>Craig</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Maginnis</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>King</surname><given-names>B.L.</given-names></name></person-group><article-title>Rearrangement in the Hypervariable Region of JC Polyomavirus Genomes Isolated from Patient Samples and Impact on Transcription Factor-Binding Sites and Disease Outcomes</article-title><source>Int. J. Mol. Sci.</source><year>2022</year><volume>23</volume><elocation-id>5699</elocation-id><pub-id pub-id-type="doi">10.3390/ijms23105699</pub-id><pub-id pub-id-type="pmid">35628509</pub-id><pub-id pub-id-type="pmcid">PMC9144386</pub-id></element-citation></ref><ref id="B24-viruses-15-00968"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tan</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Koralnik</surname><given-names>I.J.</given-names></name></person-group><article-title>Progressive Multifocal Leukoencephalopathy and Other Disorders Caused by JC Virus: Clinical Features and Pathogenesis</article-title><source>Lancet Neurol.</source><year>2010</year><volume>9</volume><fpage>425</fpage><lpage>437</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(10)70040-5</pub-id><pub-id pub-id-type="pmid">20298966</pub-id><pub-id pub-id-type="pmcid">PMC2880524</pub-id></element-citation></ref><ref id="B25-viruses-15-00968"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khanna</surname><given-names>N.</given-names></name><name name-style="western"><surname>Elzi</surname><given-names>L.</given-names></name><name name-style="western"><surname>Mueller</surname><given-names>N.J.</given-names></name><name name-style="western"><surname>Garzoni</surname><given-names>C.</given-names></name><name name-style="western"><surname>Cavassini</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fux</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Vernazza</surname><given-names>P.</given-names></name><name name-style="western"><surname>Bernasconi</surname><given-names>E.</given-names></name><name name-style="western"><surname>Battegay</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hirsch</surname><given-names>H.H.</given-names></name><etal/></person-group><article-title>Incidence and Outcome of Progressive Multifocal Leukoencephalopathy over 20 Years of the Swiss HIV Cohort Study</article-title><source>Clin. Infect. Dis.</source><year>2009</year><volume>48</volume><fpage>1459</fpage><lpage>1466</lpage><pub-id pub-id-type="doi">10.1086/598335</pub-id><pub-id pub-id-type="pmid">19348592</pub-id></element-citation></ref><ref id="B26-viruses-15-00968"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brew</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Davies</surname><given-names>N.W.S.</given-names></name><name name-style="western"><surname>Cinque</surname><given-names>P.</given-names></name><name name-style="western"><surname>Clifford</surname><given-names>D.B.</given-names></name><name name-style="western"><surname>Nath</surname><given-names>A.</given-names></name></person-group><article-title>Progressive Multifocal Leukoencephalopathy and Other Forms of JC Virus Disease</article-title><source>Nat. Rev. Neurol.</source><year>2010</year><volume>6</volume><fpage>667</fpage><lpage>679</lpage><pub-id pub-id-type="doi">10.1038/nrneurol.2010.164</pub-id><pub-id pub-id-type="pmid">21131916</pub-id></element-citation></ref><ref id="B27-viruses-15-00968"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Berger</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Cree</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>Greenberg</surname><given-names>B.</given-names></name><name name-style="western"><surname>Hemmer</surname><given-names>B.</given-names></name><name name-style="western"><surname>Ward</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>V.M.</given-names></name><name name-style="western"><surname>Merschhemke</surname><given-names>M.</given-names></name></person-group><article-title>Progressive Multifocal Leukoencephalopathy after Fingolimod Treatment</article-title><source>Neurology</source><year>2018</year><volume>90</volume><fpage>e1815</fpage><lpage>e1821</lpage><pub-id pub-id-type="doi">10.1212/WNL.0000000000005529</pub-id><pub-id pub-id-type="pmid">29669908</pub-id><pub-id pub-id-type="pmcid">PMC5957303</pub-id></element-citation></ref><ref id="B28-viruses-15-00968"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kothary</surname><given-names>N.</given-names></name><name name-style="western"><surname>Diak</surname><given-names>I.-L.</given-names></name><name name-style="western"><surname>Brinker</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bezabeh</surname><given-names>S.</given-names></name><name name-style="western"><surname>Avigan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dal Pan</surname><given-names>G.</given-names></name></person-group><article-title>Progressive Multifocal Leukoencephalopathy Associated with Efalizumab Use in Psoriasis Patients</article-title><source>J. Am. Acad. Dermatol.</source><year>2011</year><volume>65</volume><fpage>546</fpage><lpage>551</lpage><pub-id pub-id-type="doi">10.1016/j.jaad.2010.05.033</pub-id><pub-id pub-id-type="pmid">21514689</pub-id></element-citation></ref><ref id="B29-viruses-15-00968"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Keene</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Legare</surname><given-names>C.</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>E.</given-names></name><name name-style="western"><surname>Gallivan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cawthorn</surname><given-names>G.M.</given-names></name><name name-style="western"><surname>Vu</surname><given-names>D.</given-names></name></person-group><article-title>Monoclonal Antibodies and Progressive Multifocal Leukoencephalopathy</article-title><source>Can. J. Neurol. Sci.</source><year>2011</year><volume>38</volume><fpage>565</fpage><lpage>571</lpage><pub-id pub-id-type="doi">10.1017/S0317167100012105</pub-id><pub-id pub-id-type="pmid">21672696</pub-id></element-citation></ref><ref id="B30-viruses-15-00968"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Molloy</surname><given-names>E.S.</given-names></name><name name-style="western"><surname>Calabrese</surname><given-names>L.H.</given-names></name></person-group><article-title>Progressive Multifocal Leukoencephalopathy Associated with Immunosuppressive Therapy in Rheumatic Diseases: Evolving Role of Biologic Therapies</article-title><source>Arthritis Rheumatol.</source><year>2012</year><volume>64</volume><fpage>3043</fpage><lpage>3051</lpage><pub-id pub-id-type="doi">10.1002/art.34468</pub-id><pub-id pub-id-type="pmid">22422012</pub-id></element-citation></ref><ref id="B31-viruses-15-00968"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carson</surname><given-names>K.R.</given-names></name><name name-style="western"><surname>Newsome</surname><given-names>S.D.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Wagner-Johnston</surname><given-names>N.D.</given-names></name><name name-style="western"><surname>von Geldern</surname><given-names>G.</given-names></name><name name-style="western"><surname>Moskowitz</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>Moskowitz</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Rook</surname><given-names>A.H.</given-names></name><name name-style="western"><surname>Jalan</surname><given-names>P.</given-names></name><name name-style="western"><surname>Loren</surname><given-names>A.W.</given-names></name><etal/></person-group><article-title>Progressive Multifocal Leukoencephalopathy Associated with Brentuximab Vedotin Therapy: A Report of 5 Cases from the Southern Network on Adverse Reactions (SONAR) Project</article-title><source>Cancer</source><year>2014</year><volume>120</volume><fpage>2464</fpage><lpage>2471</lpage><pub-id pub-id-type="doi">10.1002/cncr.28712</pub-id><pub-id pub-id-type="pmid">24771533</pub-id><pub-id pub-id-type="pmcid">PMC4460831</pub-id></element-citation></ref><ref id="B32-viruses-15-00968"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Melis</surname><given-names>M.</given-names></name><name name-style="western"><surname>Biagi</surname><given-names>C.</given-names></name><name name-style="western"><surname>Sm&#229;brekke</surname><given-names>L.</given-names></name><name name-style="western"><surname>Nonino</surname><given-names>F.</given-names></name><name name-style="western"><surname>Buccellato</surname><given-names>E.</given-names></name><name name-style="western"><surname>Donati</surname><given-names>M.</given-names></name><name name-style="western"><surname>Vaccheri</surname><given-names>A.</given-names></name><name name-style="western"><surname>Motola</surname><given-names>D.</given-names></name></person-group><article-title>Drug-Induced Progressive Multifocal Leukoencephalopathy: A Comprehensive Analysis of the WHO Adverse Drug Reaction Database</article-title><source>CNS Drugs</source><year>2015</year><volume>29</volume><fpage>879</fpage><lpage>891</lpage><pub-id pub-id-type="doi">10.1007/s40263-015-0286-3</pub-id><pub-id pub-id-type="pmid">26507833</pub-id></element-citation></ref><ref id="B33-viruses-15-00968"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maas</surname><given-names>R.P.P.W.M.</given-names></name><name name-style="western"><surname>Muller-Hansma</surname><given-names>A.H.G.</given-names></name><name name-style="western"><surname>Esselink</surname><given-names>R.A.J.</given-names></name><name name-style="western"><surname>Murk</surname><given-names>J.-L.</given-names></name><name name-style="western"><surname>Warnke</surname><given-names>C.</given-names></name><name name-style="western"><surname>Killestein</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wattjes</surname><given-names>M.P.</given-names></name></person-group><article-title>Drug-Associated Progressive Multifocal Leukoencephalopathy: A Clinical, Radiological, and Cerebrospinal Fluid Analysis of 326 Cases</article-title><source>J. Neurol.</source><year>2016</year><volume>263</volume><fpage>2004</fpage><lpage>2021</lpage><pub-id pub-id-type="doi">10.1007/s00415-016-8217-x</pub-id><pub-id pub-id-type="pmid">27401179</pub-id><pub-id pub-id-type="pmcid">PMC5037162</pub-id></element-citation></ref><ref id="B34-viruses-15-00968"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Raisch</surname><given-names>D.W.</given-names></name><name name-style="western"><surname>Rafi</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bennett</surname><given-names>C.L.</given-names></name></person-group><article-title>Detection of Cases of Progressive Multifocal Leukoencephalopathy Associated with New Biologicals and Targeted Cancer Therapies from the FDA&#8217;s Adverse Event Reporting System</article-title><source>Expert Opin. Drug Saf.</source><year>2016</year><volume>15</volume><fpage>1003</fpage><lpage>1011</lpage><pub-id pub-id-type="doi">10.1080/14740338.2016.1198775</pub-id><pub-id pub-id-type="pmid">27268272</pub-id><pub-id pub-id-type="pmcid">PMC5020696</pub-id></element-citation></ref><ref id="B35-viruses-15-00968"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Agyemang</surname><given-names>E.</given-names></name><name name-style="western"><surname>Bailey</surname><given-names>L.</given-names></name><name name-style="western"><surname>Talbot</surname><given-names>J.</given-names></name></person-group><article-title>Additional Risk Minimisation Measures for Medicinal Products in the European Union: A Review of the Implementation and Effectiveness of Measures in the United Kingdom by One Marketing Authorisation Holder</article-title><source>Pharm. Med.</source><year>2017</year><volume>31</volume><fpage>101</fpage><lpage>112</lpage><pub-id pub-id-type="doi">10.1007/s40290-017-0184-8</pub-id><pub-id pub-id-type="pmcid">PMC5376384</pub-id><pub-id pub-id-type="pmid">28413313</pub-id></element-citation></ref><ref id="B36-viruses-15-00968"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Colin</surname><given-names>O.</given-names></name><name name-style="western"><surname>Favreli&#232;re</surname><given-names>S.</given-names></name><name name-style="western"><surname>Quillet</surname><given-names>A.</given-names></name><name name-style="western"><surname>Neau</surname><given-names>J.-P.</given-names></name><name name-style="western"><surname>Houeto</surname><given-names>J.-L.</given-names></name><name name-style="western"><surname>Lafay-Chebassier</surname><given-names>C.</given-names></name><name name-style="western"><surname>P&#233;rault-Pochat</surname><given-names>M.-C.</given-names></name></person-group><article-title>French Pharmacovigilance Network Drug-Induced Progressive Multifocal Leukoencephalopathy: A Case/Noncase Study in the French Pharmacovigilance Database</article-title><source>Fundam. Clin. Pharmacol.</source><year>2017</year><volume>31</volume><fpage>237</fpage><lpage>244</lpage><pub-id pub-id-type="doi">10.1111/fcp.12247</pub-id><pub-id pub-id-type="pmid">27736027</pub-id></element-citation></ref><ref id="B37-viruses-15-00968"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oshima</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tanimoto</surname><given-names>T.</given-names></name><name name-style="western"><surname>Yuji</surname><given-names>K.</given-names></name><name name-style="western"><surname>Tojo</surname><given-names>A.</given-names></name></person-group><article-title>Drug-Associated Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis Patients</article-title><source>Mult. Scler.</source><year>2019</year><volume>25</volume><fpage>1141</fpage><lpage>1149</lpage><pub-id pub-id-type="doi">10.1177/1352458518786075</pub-id><pub-id pub-id-type="pmid">29985084</pub-id></element-citation></ref><ref id="B38-viruses-15-00968"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Butzkueven</surname><given-names>H.</given-names></name><name name-style="western"><surname>Moore</surname><given-names>N.</given-names></name><name name-style="western"><surname>Aydemir</surname><given-names>A.</given-names></name><name name-style="western"><surname>S&#245;najalg</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bezemer</surname><given-names>I.</given-names></name><name name-style="western"><surname>Korhonen</surname><given-names>P.</given-names></name><name name-style="western"><surname>Sabid&#243;</surname><given-names>M.</given-names></name></person-group><article-title>CLARION Study Group The CLARION Study Design and Status Update: A Long-Term, Registry-Based Study Evaluating Adverse Events of Special Interest in Patients with Relapsing Multiple Sclerosis Newly Started on Cladribine Tablets</article-title><source>Curr. Med. Res. Opin.</source><year>2022</year><volume>38</volume><fpage>1167</fpage><lpage>1176</lpage><pub-id pub-id-type="doi">10.1080/03007995.2022.2059977</pub-id><pub-id pub-id-type="pmid">35357268</pub-id></element-citation></ref><ref id="B39-viruses-15-00968"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hagan</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Ender</surname><given-names>E.</given-names></name><name name-style="western"><surname>Divekar</surname><given-names>R.D.</given-names></name><name name-style="western"><surname>Pongdee</surname><given-names>T.</given-names></name><name name-style="western"><surname>Rank</surname><given-names>M.A.</given-names></name></person-group><article-title>Risk for Postmarket Black Box Warnings in FDA-Approved Monoclonal Antibodies</article-title><source>Mayo Clin. Proc. Innov. Qual. Outcomes</source><year>2022</year><volume>6</volume><fpage>69</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1016/j.mayocpiqo.2021.11.009</pub-id><pub-id pub-id-type="pmid">35024565</pub-id><pub-id pub-id-type="pmcid">PMC8724853</pub-id></element-citation></ref><ref id="B40-viruses-15-00968"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Netravathi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mahadevan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Satishchandra</surname><given-names>P.</given-names></name><name name-style="western"><surname>Shobha</surname><given-names>N.</given-names></name><name name-style="western"><surname>Mailankody</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kandavel</surname><given-names>T.</given-names></name><name name-style="western"><surname>Jitender</surname><given-names>S.</given-names></name><name name-style="western"><surname>Anantaram</surname><given-names>G.</given-names></name><name name-style="western"><surname>Nagarathna</surname><given-names>S.</given-names></name><name name-style="western"><surname>Govekar</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Progressive Multifocal Leukoencephalopathy (PML) Associated with HIV Clade C--Is Not Uncommon</article-title><source>J. Neurovirol.</source><year>2013</year><volume>19</volume><fpage>198</fpage><lpage>208</lpage><pub-id pub-id-type="doi">10.1007/s13365-013-0168-8</pub-id><pub-id pub-id-type="pmid">23700233</pub-id></element-citation></ref><ref id="B41-viruses-15-00968"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sainz-de-la-Maza</surname><given-names>S.</given-names></name><name name-style="western"><surname>Casado</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>P&#233;rez-El&#237;as</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Moreno</surname><given-names>A.</given-names></name><name name-style="western"><surname>Quereda</surname><given-names>C.</given-names></name><name name-style="western"><surname>Moreno</surname><given-names>S.</given-names></name><name name-style="western"><surname>Corral</surname><given-names>I.</given-names></name></person-group><article-title>Incidence and Prognosis of Immune Reconstitution Inflammatory Syndrome in HIV-Associated Progressive Multifocal Leucoencephalopathy</article-title><source>Eur. J. Neurol.</source><year>2016</year><volume>23</volume><fpage>919</fpage><lpage>925</lpage><pub-id pub-id-type="doi">10.1111/ene.12963</pub-id><pub-id pub-id-type="pmid">26914970</pub-id></element-citation></ref><ref id="B42-viruses-15-00968"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Graf</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Rosenkranz</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>H&#246;lzemer</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hagel</surname><given-names>C.</given-names></name><name name-style="western"><surname>Goebell</surname><given-names>E.</given-names></name><name name-style="western"><surname>Jordan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Friese</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Addo</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Schulze Zur Wiesch</surname><given-names>J.</given-names></name><name name-style="western"><surname>Beisel</surname><given-names>C.</given-names></name></person-group><article-title>Clinical Presentation and Disease Course of 37 Consecutive Cases of Progressive Multifocal Leukoencephalopathy (PML) at a German Tertiary-Care Hospital: A Retrospective Observational Study</article-title><source>Front. Neurol.</source><year>2021</year><volume>12</volume><fpage>632535</fpage><pub-id pub-id-type="doi">10.3389/fneur.2021.632535</pub-id><pub-id pub-id-type="pmid">33613439</pub-id><pub-id pub-id-type="pmcid">PMC7890249</pub-id></element-citation></ref><ref id="B43-viruses-15-00968"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Subapriya</surname><given-names>R.</given-names></name><name name-style="western"><surname>Kaur</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pasham</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Upadhaya</surname><given-names>R.</given-names></name><name name-style="western"><surname>Sriwastava</surname><given-names>S.</given-names></name></person-group><article-title>Single-Center Experience on Progressive Multifocal Leukoencephalopathy (PML) Cases, Neuroimaging Relevance, and Management at West Virginia University (WVU)</article-title><source>J. Med. Virol.</source><year>2022</year><volume>94</volume><fpage>4015</fpage><lpage>4022</lpage><pub-id pub-id-type="doi">10.1002/jmv.27804</pub-id><pub-id pub-id-type="pmid">35451090</pub-id></element-citation></ref><ref id="B44-viruses-15-00968"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kartau</surname><given-names>M.</given-names></name><name name-style="western"><surname>Auvinen</surname><given-names>E.</given-names></name><name name-style="western"><surname>Verkkoniemi-Ahola</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mannonen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Helanter&#228;</surname><given-names>I.</given-names></name><name name-style="western"><surname>Anttila</surname><given-names>V.-J.</given-names></name></person-group><article-title>JC Polyomavirus DNA Detection in Clinical Practice</article-title><source>J. Clin. Virol.</source><year>2022</year><volume>146</volume><fpage>105051</fpage><pub-id pub-id-type="doi">10.1016/j.jcv.2021.105051</pub-id><pub-id pub-id-type="pmid">34883406</pub-id></element-citation></ref><ref id="B45-viruses-15-00968"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Antinori</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cingolani</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lorenzini</surname><given-names>P.</given-names></name><name name-style="western"><surname>Giancola</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Uccella</surname><given-names>I.</given-names></name><name name-style="western"><surname>Bossolasco</surname><given-names>S.</given-names></name><name name-style="western"><surname>Grisetti</surname><given-names>S.</given-names></name><name name-style="western"><surname>Moretti</surname><given-names>F.</given-names></name><name name-style="western"><surname>Vigo</surname><given-names>B.</given-names></name><name name-style="western"><surname>Bongiovanni</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Clinical Epidemiology and Survival of Progressive Multifocal Leukoencephalopathy in the Era of Highly Active Antiretroviral Therapy: Data from the Italian Registry Investigative Neuro AIDS (IRINA)</article-title><source>J. Neurovirol.</source><year>2003</year><volume>9</volume><fpage>47</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1080/13550280390195388</pub-id><pub-id pub-id-type="pmid">12709872</pub-id></element-citation></ref><ref id="B46-viruses-15-00968"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marzocchetti</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tompkins</surname><given-names>T.</given-names></name><name name-style="western"><surname>Clifford</surname><given-names>D.B.</given-names></name><name name-style="western"><surname>Gandhi</surname><given-names>R.T.</given-names></name><name name-style="western"><surname>Kesari</surname><given-names>S.</given-names></name><name name-style="western"><surname>Berger</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Simpson</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Prosperi</surname><given-names>M.</given-names></name><name name-style="western"><surname>De Luca</surname><given-names>A.</given-names></name><name name-style="western"><surname>Koralnik</surname><given-names>I.J.</given-names></name></person-group><article-title>Determinants of Survival in Progressive Multifocal Leukoencephalopathy</article-title><source>Neurology</source><year>2009</year><volume>73</volume><fpage>1551</fpage><lpage>1558</lpage><pub-id pub-id-type="doi">10.1212/WNL.0b013e3181c0d4a1</pub-id><pub-id pub-id-type="pmid">19901246</pub-id><pub-id pub-id-type="pmcid">PMC2777072</pub-id></element-citation></ref><ref id="B47-viruses-15-00968"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mateen</surname><given-names>F.J.</given-names></name><name name-style="western"><surname>Muralidharan</surname><given-names>R.</given-names></name><name name-style="western"><surname>Carone</surname><given-names>M.</given-names></name><name name-style="western"><surname>van de Beek</surname><given-names>D.</given-names></name><name name-style="western"><surname>Harrison</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Aksamit</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Gould</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Clifford</surname><given-names>D.B.</given-names></name><name name-style="western"><surname>Nath</surname><given-names>A.</given-names></name></person-group><article-title>Progressive Multifocal Leukoencephalopathy in Transplant Recipients</article-title><source>Ann. Neurol.</source><year>2011</year><volume>70</volume><fpage>305</fpage><lpage>322</lpage><pub-id pub-id-type="doi">10.1002/ana.22408</pub-id><pub-id pub-id-type="pmid">21823157</pub-id><pub-id pub-id-type="pmcid">PMC4910883</pub-id></element-citation></ref><ref id="B48-viruses-15-00968"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jamilloux</surname><given-names>Y.</given-names></name><name name-style="western"><surname>N&#233;el</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lecouffe-Desprets</surname><given-names>M.</given-names></name><name name-style="western"><surname>F&#232;vre</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kerever</surname><given-names>S.</given-names></name><name name-style="western"><surname>Guillon</surname><given-names>B.</given-names></name><name name-style="western"><surname>Bouvry</surname><given-names>D.</given-names></name><name name-style="western"><surname>Varron</surname><given-names>L.</given-names></name><name name-style="western"><surname>Redares</surname><given-names>C.</given-names></name><name name-style="western"><surname>Dominique</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Progressive Multifocal Leukoencephalopathy in Patients with Sarcoidosis</article-title><source>Neurology</source><year>2014</year><volume>82</volume><fpage>1307</fpage><lpage>1313</lpage><pub-id pub-id-type="doi">10.1212/WNL.0000000000000318</pub-id><pub-id pub-id-type="pmid">24610328</pub-id></element-citation></ref><ref id="B49-viruses-15-00968"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kartau</surname><given-names>M.</given-names></name><name name-style="western"><surname>Verkkoniemi-Ahola</surname><given-names>A.</given-names></name><name name-style="western"><surname>Paetau</surname><given-names>A.</given-names></name><name name-style="western"><surname>Palom&#228;ki</surname><given-names>M.</given-names></name><name name-style="western"><surname>Janes</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ristola</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lappalainen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Anttila</surname><given-names>V.-J.</given-names></name></person-group><article-title>The Incidence and Predisposing Factors of John Cunningham Virus-Induced Progressive Multifocal Leukoencephalopathy in Southern Finland: A Population-Based Study</article-title><source>Open Forum Infect. Dis.</source><year>2019</year><volume>6</volume><fpage>ofz024</fpage><pub-id pub-id-type="doi">10.1093/ofid/ofz024</pub-id><pub-id pub-id-type="pmid">30815501</pub-id><pub-id pub-id-type="pmcid">PMC6386113</pub-id></element-citation></ref><ref id="B50-viruses-15-00968"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dalla-Pozza</surname><given-names>P.</given-names></name><name name-style="western"><surname>Hentzien</surname><given-names>M.</given-names></name><name name-style="western"><surname>Allavena</surname><given-names>C.</given-names></name><name name-style="western"><surname>Doe de Maindreville</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bouiller</surname><given-names>K.</given-names></name><name name-style="western"><surname>Valantin</surname><given-names>M.-A.</given-names></name><name name-style="western"><surname>Lafont</surname><given-names>E.</given-names></name><name name-style="western"><surname>Zaegel-Faucher</surname><given-names>O.</given-names></name><name name-style="western"><surname>Cheret</surname><given-names>A.</given-names></name><name name-style="western"><surname>Martin-Blondel</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Progressive Multifocal Leukoencephalopathy in Patients with Immunovirological Control and at Least 6 Months of Combination Antiretroviral Therapy</article-title><source>AIDS</source><year>2022</year><volume>36</volume><fpage>539</fpage><lpage>549</lpage><pub-id pub-id-type="doi">10.1097/QAD.0000000000003145</pub-id><pub-id pub-id-type="pmid">34873087</pub-id></element-citation></ref><ref id="B51-viruses-15-00968"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Neff</surname><given-names>R.T.</given-names></name><name name-style="western"><surname>Hurst</surname><given-names>F.P.</given-names></name><name name-style="western"><surname>Falta</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Bohen</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Lentine</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Dharnidharka</surname><given-names>V.R.</given-names></name><name name-style="western"><surname>Agodoa</surname><given-names>L.Y.</given-names></name><name name-style="western"><surname>Jindal</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Abbott</surname><given-names>K.C.</given-names></name></person-group><article-title>Progressive Multifocal Leukoencephalopathy and Use of Mycophenolate Mofetil after Kidney Transplantation</article-title><source>Transplantation</source><year>2008</year><volume>86</volume><fpage>1474</fpage><lpage>1478</lpage><pub-id pub-id-type="doi">10.1097/TP.0b013e31818b62c8</pub-id><pub-id pub-id-type="pmid">19034021</pub-id></element-citation></ref><ref id="B52-viruses-15-00968"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Molloy</surname><given-names>E.S.</given-names></name><name name-style="western"><surname>Calabrese</surname><given-names>L.H.</given-names></name></person-group><article-title>Progressive Multifocal Leukoencephalopathy: A National Estimate of Frequency in Systemic Lupus Erythematosus and Other Rheumatic Diseases</article-title><source>Arthritis Rheumatol.</source><year>2009</year><volume>60</volume><fpage>3761</fpage><lpage>3765</lpage><pub-id pub-id-type="doi">10.1002/art.24966</pub-id><pub-id pub-id-type="pmid">19950261</pub-id></element-citation></ref><ref id="B53-viruses-15-00968"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Amend</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Turnbull</surname><given-names>B.</given-names></name><name name-style="western"><surname>Foskett</surname><given-names>N.</given-names></name><name name-style="western"><surname>Napalkov</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kurth</surname><given-names>T.</given-names></name><name name-style="western"><surname>Seeger</surname><given-names>J.</given-names></name></person-group><article-title>Incidence of Progressive Multifocal Leukoencephalopathy in Patients without HIV</article-title><source>Neurology</source><year>2010</year><volume>75</volume><fpage>1326</fpage><lpage>1332</lpage><pub-id pub-id-type="doi">10.1212/WNL.0b013e3181f73600</pub-id><pub-id pub-id-type="pmid">20938025</pub-id></element-citation></ref><ref id="B54-viruses-15-00968"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Christensen</surname><given-names>K.L.Y.</given-names></name><name name-style="western"><surname>Holman</surname><given-names>R.C.</given-names></name><name name-style="western"><surname>Hammett</surname><given-names>T.A.</given-names></name><name name-style="western"><surname>Belay</surname><given-names>E.D.</given-names></name><name name-style="western"><surname>Schonberger</surname><given-names>L.B.</given-names></name></person-group><article-title>Progressive Multifocal Leukoencephalopathy Deaths in the USA, 1979&#8211;2005</article-title><source>Neuroepidemiology</source><year>2010</year><volume>35</volume><fpage>178</fpage><lpage>184</lpage><pub-id pub-id-type="doi">10.1159/000311014</pub-id><pub-id pub-id-type="pmid">20664291</pub-id></element-citation></ref><ref id="B55-viruses-15-00968"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carvour</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Harms</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Lynch</surname><given-names>C.F.</given-names></name><name name-style="western"><surname>Mayer</surname><given-names>R.R.</given-names></name><name name-style="western"><surname>Meier</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>D.</given-names></name><name name-style="western"><surname>Torner</surname><given-names>J.C.</given-names></name></person-group><article-title>Differential Survival for Men and Women with HIV/AIDS-Related Neurologic Diagnoses</article-title><source>PLoS ONE</source><year>2015</year><volume>10</volume><elocation-id>e0123119</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0123119</pub-id><pub-id pub-id-type="pmid">26107253</pub-id><pub-id pub-id-type="pmcid">PMC4480974</pub-id></element-citation></ref><ref id="B56-viruses-15-00968"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Melliez</surname><given-names>H.</given-names></name><name name-style="western"><surname>Mary-Krause</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bocket</surname><given-names>L.</given-names></name><name name-style="western"><surname>Guiguet</surname><given-names>M.</given-names></name><name name-style="western"><surname>Abgrall</surname><given-names>S.</given-names></name><name name-style="western"><surname>De Truchis</surname><given-names>P.</given-names></name><name name-style="western"><surname>Katlama</surname><given-names>C.</given-names></name><name name-style="western"><surname>Martin-Blondel</surname><given-names>G.</given-names></name><name name-style="western"><surname>Henn</surname><given-names>A.</given-names></name><name name-style="western"><surname>Revest</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Risk of Progressive Multifocal Leukoencephalopathy in the Combination Antiretroviral Therapy Era in the French Hospital Database on Human Immunodeficiency Virus (ANRS-C4)</article-title><source>Clin. Infect. Dis.</source><year>2018</year><volume>67</volume><fpage>275</fpage><lpage>282</lpage><pub-id pub-id-type="doi">10.1093/cid/ciy074</pub-id><pub-id pub-id-type="pmid">29635465</pub-id></element-citation></ref><ref id="B57-viruses-15-00968"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sipil&#228;</surname><given-names>J.O.T.</given-names></name><name name-style="western"><surname>Soilu-H&#228;nninen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rautava</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kyt&#246;</surname><given-names>V.</given-names></name></person-group><article-title>Progressive Multifocal Leukoencephalopathy in Finland: A Cross-Sectional Registry Study</article-title><source>J. Neurol.</source><year>2019</year><volume>266</volume><fpage>515</fpage><lpage>521</lpage><pub-id pub-id-type="doi">10.1007/s00415-018-09167-y</pub-id><pub-id pub-id-type="pmid">30612143</pub-id><pub-id pub-id-type="pmcid">PMC6373365</pub-id></element-citation></ref><ref id="B58-viruses-15-00968"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Joly</surname><given-names>M.</given-names></name><name name-style="western"><surname>Conte</surname><given-names>C.</given-names></name><name name-style="western"><surname>Cazanave</surname><given-names>C.</given-names></name><name name-style="western"><surname>Le Moing</surname><given-names>V.</given-names></name><name name-style="western"><surname>Tattevin</surname><given-names>P.</given-names></name><name name-style="western"><surname>Delobel</surname><given-names>P.</given-names></name><name name-style="western"><surname>Sommet</surname><given-names>A.</given-names></name><name name-style="western"><surname>Martin-Blondel</surname><given-names>G.</given-names></name></person-group><article-title>Progressive Multifocal Leukoencephalopathy: Epidemiology and Spectrum of Predisposing Conditions</article-title><source>Brain</source><year>2022</year><volume>146</volume><fpage>awac237</fpage><pub-id pub-id-type="doi">10.1093/brain/awac237</pub-id><pub-id pub-id-type="pmid">35779271</pub-id></element-citation></ref><ref id="B59-viruses-15-00968"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dastmalchi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Laki</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lundberg</surname><given-names>I.E.</given-names></name><name name-style="western"><surname>Iacobaeus</surname><given-names>E.</given-names></name></person-group><article-title>Progressive Multifocal Leukoencephalopathy in a Patient with Polymyositis: Case Report and Literature Review</article-title><source>J. Rheumatol.</source><year>2012</year><volume>39</volume><fpage>1299</fpage><lpage>1303</lpage><pub-id pub-id-type="doi">10.3899/jrheum.111126</pub-id><pub-id pub-id-type="pmid">22661423</pub-id></element-citation></ref><ref id="B60-viruses-15-00968"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ohara</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kataoka</surname><given-names>H.</given-names></name><name name-style="western"><surname>Nakamichi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Saijo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ueno</surname><given-names>S.</given-names></name></person-group><article-title>Favorable Outcome after Withdrawal of Immunosuppressant Therapy in Progressive Multifocal Leukoencephalopathy after Renal Transplantation: Case Report and Literature Review</article-title><source>J. Neurol. Sci.</source><year>2014</year><volume>341</volume><fpage>144</fpage><lpage>146</lpage><pub-id pub-id-type="doi">10.1016/j.jns.2014.03.048</pub-id><pub-id pub-id-type="pmid">24746292</pub-id></element-citation></ref><ref id="B61-viruses-15-00968"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schwenk</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ramirez-Avila</surname><given-names>L.</given-names></name><name name-style="western"><surname>Sheu</surname><given-names>S.-H.</given-names></name><name name-style="western"><surname>Wuthrich</surname><given-names>C.</given-names></name><name name-style="western"><surname>Waugh</surname><given-names>J.</given-names></name><name name-style="western"><surname>Was</surname><given-names>A.</given-names></name><name name-style="western"><surname>Degirolami</surname><given-names>U.</given-names></name><name name-style="western"><surname>Burchett</surname><given-names>S.</given-names></name><name name-style="western"><surname>Koralnik</surname><given-names>I.J.</given-names></name><name name-style="western"><surname>Ahmed</surname><given-names>A.</given-names></name></person-group><article-title>Progressive Multifocal Leukoencephalopathy in Pediatric Patients: Case Report and Literature Review</article-title><source>Pediatr. Infect. Dis. J.</source><year>2014</year><volume>33</volume><fpage>e99</fpage><lpage>e105</lpage><pub-id pub-id-type="doi">10.1097/INF.0000000000000237</pub-id><pub-id pub-id-type="pmid">24632669</pub-id><pub-id pub-id-type="pmcid">PMC4020507</pub-id></element-citation></ref><ref id="B62-viruses-15-00968"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Henegar</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Eudy</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Kharat</surname><given-names>V.</given-names></name><name name-style="western"><surname>Hill</surname><given-names>D.D.</given-names></name><name name-style="western"><surname>Bennett</surname><given-names>D.</given-names></name><name name-style="western"><surname>Haight</surname><given-names>B.</given-names></name></person-group><article-title>Progressive Multifocal Leukoencephalopathy in Patients with Systemic Lupus Erythematosus: A Systematic Literature Review</article-title><source>Lupus</source><year>2016</year><volume>25</volume><fpage>617</fpage><lpage>626</lpage><pub-id pub-id-type="doi">10.1177/0961203315622819</pub-id><pub-id pub-id-type="pmid">26743322</pub-id></element-citation></ref><ref id="B63-viruses-15-00968"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fournier</surname><given-names>A.</given-names></name><name name-style="western"><surname>Martin-Blondel</surname><given-names>G.</given-names></name><name name-style="western"><surname>Lechapt-Zalcman</surname><given-names>E.</given-names></name><name name-style="western"><surname>Dina</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kazemi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Verdon</surname><given-names>R.</given-names></name><name name-style="western"><surname>Mortier</surname><given-names>E.</given-names></name><name name-style="western"><surname>de La Blanchardi&#232;re</surname><given-names>A.</given-names></name></person-group><article-title>Immune Reconstitution Inflammatory Syndrome Unmasking or Worsening AIDS-Related Progressive Multifocal Leukoencephalopathy: A Literature Review</article-title><source>Front. Immunol.</source><year>2017</year><volume>8</volume><fpage>577</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2017.00577</pub-id><pub-id pub-id-type="pmid">28588577</pub-id><pub-id pub-id-type="pmcid">PMC5440580</pub-id></element-citation></ref><ref id="B64-viruses-15-00968"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ueno</surname><given-names>T.</given-names></name><name name-style="western"><surname>Sato</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kon</surname><given-names>T.</given-names></name><name name-style="western"><surname>Haga</surname><given-names>R.</given-names></name><name name-style="western"><surname>Nunomura</surname><given-names>J.-I.</given-names></name><name name-style="western"><surname>Nakamichi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Saijo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tomiyama</surname><given-names>M.</given-names></name></person-group><article-title>Progressive Multifocal Leukoencephalopathy Associated with Thymoma with Immunodeficiency: A Case Report and Literature Review</article-title><source>BMC Neurol.</source><year>2018</year><volume>18</volume><elocation-id>37</elocation-id><pub-id pub-id-type="doi">10.1186/s12883-018-1041-4</pub-id><pub-id pub-id-type="pmid">29631544</pub-id><pub-id pub-id-type="pmcid">PMC5891917</pub-id></element-citation></ref><ref id="B65-viruses-15-00968"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ishii</surname><given-names>K.</given-names></name><name name-style="western"><surname>Yamamoto</surname><given-names>F.</given-names></name><name name-style="western"><surname>Homma</surname><given-names>S.</given-names></name><name name-style="western"><surname>Okada</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Nakamichi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Saijo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tamaoka</surname><given-names>A.</given-names></name></person-group><article-title>Probable Progressive Multifocal Leukoencephalopathy-Immune Reconstitution Inflammatory Syndrome with Immunosuppressant Dose Reduction Following Lung Transplantation: A Case Report and Literature Review</article-title><source>BMC Neurol.</source><year>2019</year><volume>19</volume><elocation-id>263</elocation-id><pub-id pub-id-type="doi">10.1186/s12883-019-1493-1</pub-id><pub-id pub-id-type="pmid">31672142</pub-id><pub-id pub-id-type="pmcid">PMC6822459</pub-id></element-citation></ref><ref id="B66-viruses-15-00968"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hamaguchi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Suzuki</surname><given-names>K.</given-names></name><name name-style="western"><surname>Fujita</surname><given-names>H.</given-names></name><name name-style="western"><surname>Uzuka</surname><given-names>T.</given-names></name><name name-style="western"><surname>Matsuda</surname><given-names>H.</given-names></name><name name-style="western"><surname>Shishido-Hara</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Arai</surname><given-names>S.</given-names></name><name name-style="western"><surname>Nakamura</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kikuchi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Nakamichi</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Successful Treatment of Non-HIV Progressive Multifocal Leukoencephalopathy: Case Report and Literature Review</article-title><source>J. Neurol.</source><year>2020</year><volume>267</volume><fpage>731</fpage><lpage>738</lpage><pub-id pub-id-type="doi">10.1007/s00415-019-09629-x</pub-id><pub-id pub-id-type="pmid">31728711</pub-id></element-citation></ref><ref id="B67-viruses-15-00968"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Breville</surname><given-names>G.</given-names></name><name name-style="western"><surname>Koralnik</surname><given-names>I.J.</given-names></name><name name-style="western"><surname>Lalive</surname><given-names>P.H.</given-names></name></person-group><article-title>Brainstem Progressive Multifocal Leukoencephalopathy</article-title><source>Eur. J. Neurol.</source><year>2021</year><volume>28</volume><fpage>1016</fpage><lpage>1021</lpage><pub-id pub-id-type="doi">10.1111/ene.14617</pub-id><pub-id pub-id-type="pmid">33128290</pub-id><pub-id pub-id-type="pmcid">PMC8660572</pub-id></element-citation></ref><ref id="B68-viruses-15-00968"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Koutsavlis</surname><given-names>I.</given-names></name></person-group><article-title>Progressive Multifocal Leukoencephalopathy in Multiple Myeloma. A Literature Review and Lessons to Learn</article-title><source>Ann. Hematol.</source><year>2021</year><volume>100</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1007/s00277-020-04294-x</pub-id><pub-id pub-id-type="pmid">33009935</pub-id></element-citation></ref><ref id="B69-viruses-15-00968"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Edahiro</surname><given-names>T.</given-names></name><name name-style="western"><surname>Fukushima</surname><given-names>N.</given-names></name><name name-style="western"><surname>Otani</surname><given-names>T.</given-names></name><name name-style="western"><surname>Nakamori</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nakamichi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Chishaki</surname><given-names>R.</given-names></name><name name-style="western"><surname>Fujino</surname><given-names>K.</given-names></name><name name-style="western"><surname>Mino</surname><given-names>T.</given-names></name><name name-style="western"><surname>Yoshida</surname><given-names>T.</given-names></name><name name-style="western"><surname>Sugihara</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Progressive Multifocal Leukoencephalopathy in Relapsed Ph+ Acute Lymphoblastic Leukemia after Cord Blood Transplantation and Blinatumomab Treatment: A Case Report and Literature Review</article-title><source>Acta Haematol.</source><year>2022</year><volume>145</volume><fpage>655</fpage><lpage>660</lpage><pub-id pub-id-type="doi">10.1159/000526132</pub-id><pub-id pub-id-type="pmid">35896078</pub-id></element-citation></ref><ref id="B70-viruses-15-00968"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sriwastava</surname><given-names>S.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>E.</given-names></name><name name-style="western"><surname>Khalid</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Kaur</surname><given-names>A.</given-names></name><name name-style="western"><surname>Feizi</surname><given-names>P.</given-names></name></person-group><article-title>Progressive Multifocal Leukoencephalopathy in an Immunocompetent Patient: A Case Report and Review of Literature</article-title><source>J. Med. Virol.</source><year>2022</year><volume>94</volume><fpage>2860</fpage><lpage>2869</lpage><pub-id pub-id-type="doi">10.1002/jmv.27493</pub-id><pub-id pub-id-type="pmid">34854099</pub-id></element-citation></ref><ref id="B71-viruses-15-00968"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Berger</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Aksamit</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Clifford</surname><given-names>D.B.</given-names></name><name name-style="western"><surname>Davis</surname><given-names>L.</given-names></name><name name-style="western"><surname>Koralnik</surname><given-names>I.J.</given-names></name><name name-style="western"><surname>Sejvar</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Bartt</surname><given-names>R.</given-names></name><name name-style="western"><surname>Major</surname><given-names>E.O.</given-names></name><name name-style="western"><surname>Nath</surname><given-names>A.</given-names></name></person-group><article-title>PML Diagnostic Criteria: Consensus Statement from the AAN Neuroinfectious Disease Section</article-title><source>Neurology</source><year>2013</year><volume>80</volume><fpage>1430</fpage><lpage>1438</lpage><pub-id pub-id-type="doi">10.1212/WNL.0b013e31828c2fa1</pub-id><pub-id pub-id-type="pmid">23568998</pub-id><pub-id pub-id-type="pmcid">PMC3662270</pub-id></element-citation></ref><ref id="B72-viruses-15-00968"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nakamichi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Mizusawa</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yamada</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kishida</surname><given-names>S.</given-names></name><name name-style="western"><surname>Miura</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Shimokawa</surname><given-names>T.</given-names></name><name name-style="western"><surname>Takasaki</surname><given-names>T.</given-names></name><name name-style="western"><surname>Lim</surname><given-names>C.-K.</given-names></name><name name-style="western"><surname>Kurane</surname><given-names>I.</given-names></name><name name-style="western"><surname>Saijo</surname><given-names>M.</given-names></name></person-group><article-title>Characteristics of Progressive Multifocal Leukoencephalopathy Clarified through Internet-Assisted Laboratory Surveillance in Japan</article-title><source>BMC Neurol.</source><year>2012</year><volume>12</volume><elocation-id>121</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2377-12-121</pub-id><pub-id pub-id-type="pmid">23066763</pub-id><pub-id pub-id-type="pmcid">PMC3495800</pub-id></element-citation></ref><ref id="B73-viruses-15-00968"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nakamichi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kishida</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tanaka</surname><given-names>K.</given-names></name><name name-style="western"><surname>Suganuma</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sano</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Sano</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kanda</surname><given-names>T.</given-names></name><name name-style="western"><surname>Maeda</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kira</surname><given-names>J.-I.</given-names></name><name name-style="western"><surname>Itoh</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Sequential Changes in the Non-Coding Control Region Sequences of JC Polyomaviruses from the Cerebrospinal Fluid of Patients with Progressive Multifocal Leukoencephalopathy</article-title><source>Arch. Virol.</source><year>2013</year><volume>158</volume><fpage>639</fpage><lpage>650</lpage><pub-id pub-id-type="doi">10.1007/s00705-012-1532-3</pub-id><pub-id pub-id-type="pmid">23138154</pub-id></element-citation></ref><ref id="B74-viruses-15-00968"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nakamichi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Tajima</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lim</surname><given-names>C.-K.</given-names></name><name name-style="western"><surname>Saijo</surname><given-names>M.</given-names></name></person-group><article-title>High-Resolution Melting Analysis for Mutation Scanning in the Non-Coding Control Region of JC Polyomavirus from Patients with Progressive Multifocal Leukoencephalopathy</article-title><source>Arch. Virol.</source><year>2014</year><volume>159</volume><fpage>1687</fpage><lpage>1696</lpage><pub-id pub-id-type="doi">10.1007/s00705-014-1988-4</pub-id><pub-id pub-id-type="pmid">24463953</pub-id></element-citation></ref><ref id="B75-viruses-15-00968"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nakamichi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kawamoto</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ishii</surname><given-names>J.</given-names></name><name name-style="western"><surname>Saijo</surname><given-names>M.</given-names></name></person-group><article-title>Improving Detection of JC Virus by Ultrafiltration of Cerebrospinal Fluid before Polymerase Chain Reaction for the Diagnosis of Progressive Multifocal Leukoencephalopathy</article-title><source>BMC Neurol.</source><year>2019</year><volume>19</volume><elocation-id>252</elocation-id><pub-id pub-id-type="doi">10.1186/s12883-019-1476-2</pub-id><pub-id pub-id-type="pmid">31653203</pub-id><pub-id pub-id-type="pmcid">PMC6815041</pub-id></element-citation></ref><ref id="B76-viruses-15-00968"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nakamichi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Inoue</surname><given-names>N.</given-names></name><name name-style="western"><surname>Shimokawa</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kurane</surname><given-names>I.</given-names></name><name name-style="western"><surname>Lim</surname><given-names>C.-K.</given-names></name><name name-style="western"><surname>Saijo</surname><given-names>M.</given-names></name></person-group><article-title>Detection of Human Herpesviruses in the Cerebrospinal Fluid from Patients Diagnosed with or Suspected of Having Progressive Multifocal Leukoencephalopathy</article-title><source>BMC Neurol.</source><year>2013</year><volume>13</volume><elocation-id>200</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2377-13-200</pub-id><pub-id pub-id-type="pmid">24330281</pub-id><pub-id pub-id-type="pmcid">PMC3878787</pub-id></element-citation></ref><ref id="B77-viruses-15-00968"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nakamichi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kurane</surname><given-names>I.</given-names></name><name name-style="western"><surname>Saijo</surname><given-names>M.</given-names></name></person-group><article-title>Evaluation of a Quantitative Real-Time PCR Assay for the Detection of JC Polyomavirus DNA in Cerebrospinal Fluid without Nucleic Acid Extraction</article-title><source>Jpn. J. Infect. Dis.</source><year>2011</year><volume>64</volume><fpage>211</fpage><lpage>216</lpage><pub-id pub-id-type="doi">10.7883/yoken.64.211</pub-id><pub-id pub-id-type="pmid">21617305</pub-id></element-citation></ref><ref id="B78-viruses-15-00968"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nakamichi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Lim</surname><given-names>C.-K.</given-names></name><name name-style="western"><surname>Saijo</surname><given-names>M.</given-names></name></person-group><article-title>Stability of JC Virus DNA in Cerebrospinal Fluid Specimens Preserved with Guanidine Lysis Buffer for Quantitative PCR Testing</article-title><source>Jpn. J. Infect. Dis.</source><year>2014</year><volume>67</volume><fpage>307</fpage><lpage>310</lpage><pub-id pub-id-type="doi">10.7883/yoken.67.307</pub-id><pub-id pub-id-type="pmid">25056080</pub-id></element-citation></ref><ref id="B79-viruses-15-00968"><label>79.</label><element-citation publication-type="webpage"><article-title>Result of the Population Estimates: Statistics Bureau Statistics Bureau</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.stat.go.jp/english/data/jinsui/2.html" ext-link-type="uri">https://www.stat.go.jp/english/data/jinsui/2.html</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-03-03">(accessed on 3 March 2023)</date-in-citation></element-citation></ref><ref id="B80-viruses-15-00968"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matsuoka</surname><given-names>S.</given-names></name><name name-style="western"><surname>Nagashima</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sadamasu</surname><given-names>K.</given-names></name><name name-style="western"><surname>Mori</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kawahata</surname><given-names>T.</given-names></name><name name-style="western"><surname>Zaitsu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Nakamura</surname><given-names>A.</given-names></name><name name-style="western"><surname>de Souza</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Matano</surname><given-names>T.</given-names></name></person-group><article-title>Estimating HIV-1 Incidence in Japan from the Proportion of Recent Infections</article-title><source>Prev. Med. Rep.</source><year>2019</year><volume>16</volume><fpage>100994</fpage><pub-id pub-id-type="doi">10.1016/j.pmedr.2019.100994</pub-id><pub-id pub-id-type="pmid">31720200</pub-id><pub-id pub-id-type="pmcid">PMC6838929</pub-id></element-citation></ref><ref id="B81-viruses-15-00968"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anand</surname><given-names>P.</given-names></name><name name-style="western"><surname>Hotan</surname><given-names>G.C.</given-names></name><name name-style="western"><surname>Vogel</surname><given-names>A.</given-names></name><name name-style="western"><surname>Venna</surname><given-names>N.</given-names></name><name name-style="western"><surname>Mateen</surname><given-names>F.J.</given-names></name></person-group><article-title>Progressive Multifocal Leukoencephalopathy: A 25-Year Retrospective Cohort Study</article-title><source>Neurol. Neuroimmunol. Neuroinflamm.</source><year>2019</year><volume>6</volume><fpage>e618</fpage><pub-id pub-id-type="doi">10.1212/NXI.0000000000000618</pub-id><pub-id pub-id-type="pmid">31554669</pub-id><pub-id pub-id-type="pmcid">PMC6814409</pub-id></element-citation></ref><ref id="B82-viruses-15-00968"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Govender</surname><given-names>R.D.</given-names></name><name name-style="western"><surname>Hashim</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Mustafa</surname><given-names>H.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>G.</given-names></name></person-group><article-title>Global Epidemiology of HIV/AIDS: A Resurgence in North America and Europe</article-title><source>J. Epidemiol. Glob. Health</source><year>2021</year><volume>11</volume><fpage>296</fpage><lpage>301</lpage><pub-id pub-id-type="doi">10.2991/jegh.k.210621.001</pub-id><pub-id pub-id-type="pmid">34270183</pub-id><pub-id pub-id-type="pmcid">PMC8435868</pub-id></element-citation></ref><ref id="B83-viruses-15-00968"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nakahara</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tomaske</surname><given-names>L.</given-names></name><name name-style="western"><surname>Kume</surname><given-names>K.</given-names></name><name name-style="western"><surname>Takata</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kamada</surname><given-names>M.</given-names></name><name name-style="western"><surname>Deguchi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kufukihara</surname><given-names>K.</given-names></name><name name-style="western"><surname>Schneider</surname><given-names>R.</given-names></name><name name-style="western"><surname>Gold</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ayzenberg</surname><given-names>I.</given-names></name></person-group><article-title>Three Cases of Non-Carryover Fingolimod-PML: Is the Risk in Japan Increased?</article-title><source>Neurol. Neuroimmunol. Neuroinflamm.</source><year>2019</year><volume>6</volume><fpage>e559</fpage><pub-id pub-id-type="doi">10.1212/NXI.0000000000000559</pub-id><pub-id pub-id-type="pmid">31044147</pub-id><pub-id pub-id-type="pmcid">PMC6467684</pub-id></element-citation></ref><ref id="B84-viruses-15-00968"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kawachi</surname><given-names>I.</given-names></name><name name-style="western"><surname>Otaka</surname><given-names>H.</given-names></name><name name-style="western"><surname>Iwasaki</surname><given-names>K.</given-names></name><name name-style="western"><surname>Takeshima</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ueda</surname><given-names>K.</given-names></name></person-group><article-title>Treatment Status and Healthcare Cost Trends for Patients with Multiple Sclerosis in Japan: A Claims Database Analysis</article-title><source>Neurol. Ther.</source><year>2022</year><volume>11</volume><fpage>1253</fpage><lpage>1268</lpage><pub-id pub-id-type="doi">10.1007/s40120-022-00374-4</pub-id><pub-id pub-id-type="pmid">35713761</pub-id><pub-id pub-id-type="pmcid">PMC9338194</pub-id></element-citation></ref><ref id="B85-viruses-15-00968"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gheuens</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pierone</surname><given-names>G.</given-names></name><name name-style="western"><surname>Peeters</surname><given-names>P.</given-names></name><name name-style="western"><surname>Koralnik</surname><given-names>I.J.</given-names></name></person-group><article-title>Progressive Multifocal Leukoencephalopathy in Individuals with Minimal or Occult Immunosuppression</article-title><source>J. Neurol. Neurosurg. Psychiatry</source><year>2010</year><volume>81</volume><fpage>247</fpage><lpage>254</lpage><pub-id pub-id-type="doi">10.1136/jnnp.2009.187666</pub-id><pub-id pub-id-type="pmid">19828476</pub-id><pub-id pub-id-type="pmcid">PMC2889486</pub-id></element-citation></ref><ref id="B86-viruses-15-00968"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boziki</surname><given-names>M.</given-names></name><name name-style="western"><surname>Metallidis</surname><given-names>S.</given-names></name><name name-style="western"><surname>Habidou</surname><given-names>E.</given-names></name><name name-style="western"><surname>Afrantou</surname><given-names>T.</given-names></name><name name-style="western"><surname>Bakirtzis</surname><given-names>C.</given-names></name><name name-style="western"><surname>Cheva</surname><given-names>A.</given-names></name><name name-style="western"><surname>Finitsis</surname><given-names>S.</given-names></name><name name-style="western"><surname>Grigoriadis</surname><given-names>N.</given-names></name></person-group><article-title>Progressive Multifocal Leukoencephalopathy in an Elderly Immunocompetent-Appearing Patient: Relevance with L-Selectin (CD62L) Expression and Immunosenescence</article-title><source>Clin. Neurol. Neurosurg.</source><year>2021</year><volume>205</volume><fpage>106625</fpage><pub-id pub-id-type="doi">10.1016/j.clineuro.2021.106625</pub-id><pub-id pub-id-type="pmid">33892220</pub-id></element-citation></ref><ref id="B87-viruses-15-00968"><label>87.</label><element-citation publication-type="webpage"><article-title>World Health Statistics 2022: Monitoring Health for the SDGs, Sustainable Development Goals</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.who.int/publications-detail-redirect/9789240051157" ext-link-type="uri">https://www.who.int/publications-detail-redirect/9789240051157</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-03-03">(accessed on 3 March 2023)</date-in-citation></element-citation></ref><ref id="B88-viruses-15-00968"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Warnke</surname><given-names>C.</given-names></name><name name-style="western"><surname>von Geldern</surname><given-names>G.</given-names></name><name name-style="western"><surname>Markwerth</surname><given-names>P.</given-names></name><name name-style="western"><surname>Dehmel</surname><given-names>T.</given-names></name><name name-style="western"><surname>Hoepner</surname><given-names>R.</given-names></name><name name-style="western"><surname>Gold</surname><given-names>R.</given-names></name><name name-style="western"><surname>Pawlita</surname><given-names>M.</given-names></name><name name-style="western"><surname>K&#252;mpfel</surname><given-names>T.</given-names></name><name name-style="western"><surname>M&#228;urer</surname><given-names>M.</given-names></name><name name-style="western"><surname>Stangel</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Cerebrospinal Fluid JC Virus Antibody Index for Diagnosis of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy</article-title><source>Ann. Neurol.</source><year>2014</year><volume>76</volume><fpage>792</fpage><lpage>801</lpage><pub-id pub-id-type="doi">10.1002/ana.24153</pub-id><pub-id pub-id-type="pmid">24729444</pub-id><pub-id pub-id-type="pmcid">PMC4194179</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="viruses-15-00968-f001" orientation="portrait"><label>Figure 1</label><caption><p>Track record of laboratory surveillance of PML based on PCR testing for JCV in CSF samples. (<bold>A</bold>) Number of CSF-JCV testing performed per year during the 4-year start-up period (FY2007&#8211;2010) and the study period (FY2011&#8211;2020). The result includes follow-up JCV testing after PML diagnosis. (<bold>B</bold>) Types of requests for CSF-JCV testing from medical departments to the NIID. The requests for CSF-JCV testing for new suspected PML cases in each fiscal year, excluding follow-up testing after PML diagnosis, were classified into three categories: direct contact through the websites, repeat requests from departments that had previously performed the test, and others. (<bold>C</bold>) Hospital departments of physicians who submitted requests for CSF-JCV testing to the NIID. (<bold>D</bold>) Number of new patients with suspected PML tested for CSF-JCV in each fiscal year. (<bold>E</bold>) Number of new patients with JCV-positive CSF in each fiscal year. (<bold>F</bold>) Proportion of patients with JCV-positive CSF among newly tested individuals in each fiscal year.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="viruses-15-00968-g001.jpg"/></fig><fig position="float" id="viruses-15-00968-f002" orientation="portrait"><label>Figure 2</label><caption><p>Geographic distribution patterns of individuals tested for JCV in the CSF. All individuals tested (<bold>A</bold>) and patients with JCV-positive CSF (<bold>B</bold>) during the study period (FY2011&#8211;2020) are shown. Each prefecture in Japan is color-coded according to the number of individuals. (<bold>C</bold>) The hierarchical cluster analysis of the proportion of patients with JCV-positive CSF among individuals in each prefecture. Japanese prefectures were divided into five clusters according to the CSF-JCV-positivity rates. The dots indicate the positivity rates in each prefecture. The thick horizontal line within each box is the median, and the lower and upper boundaries are the 25th and 75th percentiles, respectively. Vertical whiskers extend to minimum and maximum values. (<bold>D</bold>) Distribution of hierarchical clusters based on CSF-JCV-positivity rates in Japan. Each prefecture is color-coded according to cluster type.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="viruses-15-00968-g002.jpg"/></fig><fig position="float" id="viruses-15-00968-f003" orientation="portrait"><label>Figure 3</label><caption><p>Underlying disease categories of patients with JCV-positive CSF during the study period. The underlying conditions of patients with JCV-positive CSF identified in 10 years (FY2011&#8211;2020) are classified into seven categories: HIV infection (<italic toggle="yes">n</italic> = 57), hematological disorders (<italic toggle="yes">n</italic> = 78), autoimmune disorders (<italic toggle="yes">n</italic> = 75), organ transplantation (<italic toggle="yes">n</italic> = 12), solid tumors (<italic toggle="yes">n</italic> = 8), other diseases (<italic toggle="yes">n</italic> = 40), and none/unknown (<italic toggle="yes">n</italic> = 18). Percentages for each category are shown. cART, combined antiretroviral therapy. All percentages are rounded to two decimal places.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="viruses-15-00968-g003.jpg"/></fig><fig position="float" id="viruses-15-00968-f004" orientation="portrait"><label>Figure 4</label><caption><p>Age and sex distribution patterns of patients with JCV-positive CSF. Patients with JCV-positive CSF during the study period (<bold>A</bold>) were divided into five groups based on underlying conditions: HIV infection (<bold>B</bold>), hematologic disorders (<bold>C</bold>), autoimmune disorders (<bold>D</bold>), other diseases (<bold>E</bold>), and none/unknown (<bold>F</bold>). The &#8220;other diseases&#8221; group includes patients with a history of organ transplantation, solid tumors, or comorbidities of multiple underlying diseases. The vertical axes show the number of patients, and the numbers below the bars indicate the age groups by decade.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="viruses-15-00968-g004.jpg"/></fig><fig position="float" id="viruses-15-00968-f005" orientation="portrait"><label>Figure 5</label><caption><p>Viral DNA levels in patients with JCV-positive CSF. Patients with JCV-positive CSF during the study period (<bold>A</bold>) were classified into five groups based on underlying conditions: HIV infection (<bold>B</bold>), hematologic disorders (<bold>C</bold>), autoimmune disorders (<bold>D</bold>), other diseases (<bold>E</bold>), and none/unknown (<bold>F</bold>). The copy numbers of the JCV genome in the initial CSF testing that presented positive reactions were indicated using the combinations of beeswarm plots and box-and-whisker plots. In each panel, the data are divided into the first period, when the standard PCR testing was used (FY2011&#8211;2015, <bold>left</bold>), and the second period, when the ultrasensitive PCR testing was implemented (FY2016&#8211;2020, <bold>right</bold>). The vertical axes show the logarithm of the JCV loads measured by quantitative PCR assay. The thick horizontal line within each box is the median, and the lower and upper limits are the 25th and 75th percentiles, respectively. Vertical whiskers extend to 1.5 times the interquartile range of the data. &#8220;NS&#8221; indicates no significant difference between the two groups.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="viruses-15-00968-g005.jpg"/></fig><table-wrap position="float" id="viruses-15-00968-t001" orientation="portrait"><object-id pub-id-type="pii">viruses-15-00968-t001_Table 1</object-id><label>Table 1</label><caption><p>Underlying disease categories and detection rates in patients with JCV-positive CSF.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Category</th><th colspan="6" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">No. (%) of JCV-Positive Cases <sup>a</sup></th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1"><italic toggle="yes">p</italic>-Value <sup>c</sup></th></tr><tr><th colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Entire Period <sup>b</sup></th><th colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">FY2011&#8211;2015</th><th colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">FY2016&#8211;2020</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HIV infection</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">57/210</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(27.1)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">28/135</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(20.7)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">29/75</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(38.7)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.006 *</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hematological disorders</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">78/305</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(25.6)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">29/162</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(17.9)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">49/143</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(34.3)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.001 *</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Autoimmune disorders</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">75/331</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(22.7)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">23/135</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(17.0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">52/196</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(26.5)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.045 *</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Organ transplantation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12/47</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(25.5)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6/30</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(20.0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6/17</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(35.3)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.306</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Solid organ tumors</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8/90</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(8.9)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4/58</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(6.9)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4/32</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(12.5)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.447</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Other diseases</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">40/171</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(23.4)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10/105</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(9.5)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">30/66</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(45.5)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001 *</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">None/unknown</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">18/383</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(4.7)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2/246</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(0.8)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">16/137</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(11.7)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001 *</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Total</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">288/1537</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(18.7)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">102/871</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(11.7)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">186/666</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(27.9)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001 *</td></tr></tbody></table><table-wrap-foot><fn><p>Abbreviations: CSF, cerebrospinal fluid; FY, fiscal years; HIV, human immunodeficiency virus; JCV, JC virus. <sup>a</sup> The number of JCV-positive cases and positive rates (%) are indicated. <sup>b</sup> Entire period indicates FY2011&#8211;2020. <sup>c</sup> The positive rates of CSF-JCV in FY2011&#8211;2015 and FY2016&#8211;2020 are statistically analyzed using Fisher&#8217;s exact test. Significant differences are indicated by asterisks (<italic toggle="yes">p</italic> &lt; 0.05).</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="viruses-15-00968-t002" orientation="portrait"><object-id pub-id-type="pii">viruses-15-00968-t002_Table 2</object-id><label>Table 2</label><caption><p>PCR-based detection of JCV in CSF specimens from patients with hematological disorders.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Underlying Disease <sup>b</sup></th><th colspan="6" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">No. (%) of JCV-Positive Cases <sup>a</sup></th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">% of Total <sup>d</sup></th></tr><tr><th colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">FY2011&#8211;2015</th><th colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">FY2016&#8211;2020</th><th colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Entire Period <sup>c</sup></th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Diffuse large B-cell lymphoma</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7/26</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(26.9)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8/32</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(25.0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15/58</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(25.9)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">19.2</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Multiple myeloma</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(33.3)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8/19</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(42.1)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9/22</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(40.9)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11.5</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Chronic lymphocytic leukemia</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3/6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(50.0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5/6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(83.3)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8/12</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(66.7)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10.3</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Non-Hodgkin lymphoma (unspecified)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2/20</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(10.0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6/15</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(40.0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8/35</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(22.9)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10.3</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mucosa-associated lymphoid tissue lymphoma</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3/5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(60.0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(50.0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4/7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(57.1)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.1</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Follicular lymphoma</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/10</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(10.0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3/9</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(33.3)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4/19</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(21.1)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.1</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Essential thrombocythemia</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722; <sup>e</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3/3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(100)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3/3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(100)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.8</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Acute myeloid leukemia</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2/19</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(10.5)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(16.7)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3/25</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(12.0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.8</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Adult T-cell leukemia/lymphoma</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2/13</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(15.4)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/12</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(8.3)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3/25</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(12.0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.8</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Acute lymphoid leukemia</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/16</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(6.3)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2/10</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(20.0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3/26</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(11.5)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.8</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Primary macroglobulinemia</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2/3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(66.7)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2/3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(66.7)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.6</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Idiopathic CD4 lymphocytopenia</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(50.0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(100)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2/3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(66.7)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.6</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hodgkin lymphoma</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2/2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(100)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2/6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(33.3)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.6</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Angioimmunoblastic T-cell lymphoma</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(100)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(100)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.3</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Thyroid lymphoma</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(100)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(100)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.3</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Small lymphocytic lymphoma</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(100)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(100)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.3</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hypereosinophilic syndrome</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(100)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(100)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.3</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">S&#233;zary syndrome</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(100)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(100)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.3</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mycosis fungoides</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(100)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(100)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.3</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mantle cell lymphoma</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(100)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(50.0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.3</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lymphoplasmacytic lymphoma</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(100)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(33.3)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.3</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Aplastic anemia</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(50.0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(33.3)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.3</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lymphoblastic lymphoma</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(33.3)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(25.0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.3</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Chronic myeloid leukemia</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(25.0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(14.3)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.3</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Myelodysplastic syndrome</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(25.0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/9</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(11.1)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.3</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Other diseases</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/18</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/9</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/27</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Total</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">29/162</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(17.9)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">49/143</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(34.3)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">78/305</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(25.6)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100</td></tr></tbody></table><table-wrap-foot><fn><p>Abbreviations: CD, cluster of differentiation; CSF, cerebrospinal fluid; FY, fiscal years; JCV, JC virus. <sup>a</sup> Numbers of JCV-positive cases and positive rates (%). <sup>b</sup> Underlying diseases are sorted by the number of positive cases for FY2011&#8211;2020. If the number of positive cases is the same, then they are ranked by a positive rate. <sup>c</sup> Entire period indicates FY2011&#8211;2020. <sup>d</sup> Percentages of underlying disease among all JCV-positive cases with hematological disorders for the entire period. <sup>e</sup> The minus symbol indicates not applicable.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="viruses-15-00968-t003" orientation="portrait"><object-id pub-id-type="pii">viruses-15-00968-t003_Table 3</object-id><label>Table 3</label><caption><p>PCR-based detection of JCV in CSF specimens from patients with autoimmune disorders.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Underlying Disease <sup>b</sup></th><th colspan="6" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">No. (%) of JCV-Positive Cases <sup>a</sup></th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">% of Total <sup>d</sup></th></tr><tr><th colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">FY2011&#8211;2015</th><th colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">FY2016&#8211;2020</th><th colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Entire Period <sup>c</sup></th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Systemic lupus erythematosus</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13/36</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(36.1)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">21/37</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(56.8)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">34/73</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(46.6)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">45.3</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rheumatoid arthritis</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2/31</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(6.5)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8/34</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(23.5)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10/65</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(15.4)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13.3</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Multiple sclerosis</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/9</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(11.1)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6/58</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(10.3)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7/67</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(10.4)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9.3</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dermatomyositis</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(50.0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3/4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(75.0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4/6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(66.7)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.3</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Autoimmune hemolytic anemia</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722; <sup>e</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3/3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(100)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3/3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(100)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.0</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Eosinophilic granulomatosis with <break/>polyangiitis</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(50.0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2/3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(67.0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3/5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(60.0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.0</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sj&#246;gren syndrome</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(50.0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2/4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(50.0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3/6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(50.0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.0</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antineutrophil cytoplasmic antibody- <break/>associated vasculitis</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(33.3)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2/6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(33.3)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3/9</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(33.3)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.0</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pemphigus foliaceus</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(100)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(100)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2/2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(100)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.7</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Autoimmune hepatitis</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(100)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(50.0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.3</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Systemic scleroderma</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(100)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(33.3)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.3</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Polymyalgia rheumatica</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(33.3)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(25.0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.3</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Myelin oligodendrocyte glycoprotein <break/>antibody-associated disease</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(25.0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(25.0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.3</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Granulomatosis with polyangiitis</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(33.3)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(20.0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.3</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Microscopic polyangiitis</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(50.0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(14.3)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.3</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Other diseases</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/35</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/35</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/70</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Total</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">23/135</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(17.0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">52/196</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(26.5)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">75/331</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(22.7)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100</td></tr></tbody></table><table-wrap-foot><fn><p>Abbreviations: CSF, cerebrospinal fluid; FY, fiscal years; JCV, JC virus. <sup>a</sup> Numbers of JCV-positive cases and positive rates (%). <sup>b</sup> Underlying diseases are sorted by the number of positive cases for FY2011&#8211;2020. If the number of positive cases is the same, then they are ranked by a positive rate. <sup>c</sup> Entire period indicates FY2011&#8211;2020. <sup>d</sup> Percentages of underlying disease among all JCV-positive cases with autoimmune disorders for the entire period. <sup>e</sup> The minus symbol indicates not applicable.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="viruses-15-00968-t004" orientation="portrait"><object-id pub-id-type="pii">viruses-15-00968-t004_Table 4</object-id><label>Table 4</label><caption><p>Complications of autoimmune disorders in patients with JCV-positive CSF.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="middle" style="border-top:solid thin" colspan="1">Underlying Diseases <sup>a</sup></th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin" colspan="1">Complications</th><th colspan="3" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Entire Period (FY2011&#8211;2020)</th></tr><tr><th colspan="2" align="center" valign="middle" rowspan="1">No. (%) of JCV-Positive Cases <sup>b</sup></th><th align="center" valign="middle" rowspan="1" colspan="1">% of Disease <sup>c</sup></th></tr></thead><tbody><tr><td rowspan="9" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Systemic lupus erythematosus</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">None</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">10/32</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">(31.3)</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">29.4</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Lupus nephritis</td><td align="center" valign="middle" rowspan="1" colspan="1">12/22</td><td align="center" valign="middle" rowspan="1" colspan="1">(54.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">35.3</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Antiphospholipid syndrome</td><td align="center" valign="middle" rowspan="1" colspan="1">4/4</td><td align="center" valign="middle" rowspan="1" colspan="1">(100)</td><td align="center" valign="middle" rowspan="1" colspan="1">11.8</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Lupus nephritis, Sj&#246;gren syndrome</td><td align="center" valign="middle" rowspan="1" colspan="1">2/2</td><td align="center" valign="middle" rowspan="1" colspan="1">(100)</td><td align="center" valign="middle" rowspan="1" colspan="1">5.9</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Rheumatoid arthritis</td><td align="center" valign="middle" rowspan="1" colspan="1">2/2</td><td align="center" valign="middle" rowspan="1" colspan="1">(100)</td><td align="center" valign="middle" rowspan="1" colspan="1">5.9</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Sj&#246;gren syndrome</td><td align="center" valign="middle" rowspan="1" colspan="1">2/5</td><td align="center" valign="middle" rowspan="1" colspan="1">(40.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">5.9</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Non-Hodgkin lymphoma</td><td align="center" valign="middle" rowspan="1" colspan="1">1/1</td><td align="center" valign="middle" rowspan="1" colspan="1">(100)</td><td align="center" valign="middle" rowspan="1" colspan="1">2.9</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Systemic scleroderma, polymyositis</td><td align="center" valign="middle" rowspan="1" colspan="1">1/1</td><td align="center" valign="middle" rowspan="1" colspan="1">(100)</td><td align="center" valign="middle" rowspan="1" colspan="1">2.9</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Others</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td></tr><tr><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Rheumatoid arthritis</td><td align="center" valign="middle" rowspan="1" colspan="1">None</td><td align="center" valign="middle" rowspan="1" colspan="1">6/44</td><td align="center" valign="middle" rowspan="1" colspan="1">(13.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">60.0</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Mixed connective tissue disease, malignant lymphoma</td><td align="center" valign="middle" rowspan="1" colspan="1">1/1</td><td align="center" valign="middle" rowspan="1" colspan="1">(100)</td><td align="center" valign="middle" rowspan="1" colspan="1">10.0</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Hodgkin lymphoma</td><td align="center" valign="middle" rowspan="1" colspan="1">1/1</td><td align="center" valign="middle" rowspan="1" colspan="1">(100)</td><td align="center" valign="middle" rowspan="1" colspan="1">10.0</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Non-Hodgkin lymphoma</td><td align="center" valign="middle" rowspan="1" colspan="1">1/5</td><td align="center" valign="middle" rowspan="1" colspan="1">(20.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">10.0</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Chronic kidney disease</td><td align="center" valign="middle" rowspan="1" colspan="1">1/6</td><td align="center" valign="middle" rowspan="1" colspan="1">(16.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">10.0</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Others</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td></tr><tr><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Multiple sclerosis</td><td align="center" valign="middle" rowspan="1" colspan="1">None</td><td align="center" valign="middle" rowspan="1" colspan="1">7/64</td><td align="center" valign="middle" rowspan="1" colspan="1">(10.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">100</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Rheumatoid arthritis, non-Hodgkin lymphoma</td><td align="center" valign="middle" rowspan="1" colspan="1">0/1</td><td align="center" valign="middle" rowspan="1" colspan="1">(0)</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Hyperthyroidism</td><td align="center" valign="middle" rowspan="1" colspan="1">0/1</td><td align="center" valign="middle" rowspan="1" colspan="1">(0)</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Beh&#231;et disease</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Autoimmune hemolytic anemia</td><td align="center" valign="middle" rowspan="1" colspan="1">None</td><td align="center" valign="middle" rowspan="1" colspan="1">2/2</td><td align="center" valign="middle" rowspan="1" colspan="1">(100)</td><td align="center" valign="middle" rowspan="1" colspan="1">66.7</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Malignant lymphoma</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(100)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">33.3</td></tr><tr><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Sj&#246;gren syndrome</td><td align="center" valign="middle" rowspan="1" colspan="1">None</td><td align="center" valign="middle" rowspan="1" colspan="1">1/2</td><td align="center" valign="middle" rowspan="1" colspan="1">(50.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">33.3</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Non-Hodgkin lymphoma</td><td align="center" valign="middle" rowspan="1" colspan="1">2/2</td><td align="center" valign="middle" rowspan="1" colspan="1">(100)</td><td align="center" valign="middle" rowspan="1" colspan="1">66.7</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Chronic hepatitis C</td><td align="center" valign="middle" rowspan="1" colspan="1">0/1</td><td align="center" valign="middle" rowspan="1" colspan="1">(0)</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Interstitial pneumonia</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">ANCA-associated vasculitis</td><td align="center" valign="middle" rowspan="1" colspan="1">None</td><td align="center" valign="middle" rowspan="1" colspan="1">1/6</td><td align="center" valign="middle" rowspan="1" colspan="1">(16.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">33.3</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">ANCA-associated glomerulonephritis</td><td align="center" valign="middle" rowspan="1" colspan="1">2/2</td><td align="center" valign="middle" rowspan="1" colspan="1">(100)</td><td align="center" valign="middle" rowspan="1" colspan="1">66.7</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IgG4-related disease</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Microscopic polyangiitis</td><td align="center" valign="middle" rowspan="1" colspan="1">None</td><td align="center" valign="middle" rowspan="1" colspan="1">0/5</td><td align="center" valign="middle" rowspan="1" colspan="1">(0)</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Chronic kidney disease, interstitial pneumonia</td><td align="center" valign="middle" rowspan="1" colspan="1">0/1</td><td align="center" valign="middle" rowspan="1" colspan="1">(0)</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Chronic kidney disease</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(100)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Total</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722; <sup>d</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">61/230</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(26.5)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;</td></tr></tbody></table><table-wrap-foot><fn><p>Abbreviations: ANCA, antineutrophil cytoplasmic antibody; CSF, cerebrospinal fluid; FY, fiscal years; IgG4, immunoglobulin G4; JCV, JC virus; NA, not applicable. <sup>a</sup> Autoimmune disorders without complications are excluded. <sup>b</sup> Numbers of JCV-positive cases and positive rates (%). <sup>c</sup> Percentages of JCV-positive cases in each underlying disease. <sup>d</sup> The minus symbol indicates not applicable.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="viruses-15-00968-t005" orientation="portrait"><object-id pub-id-type="pii">viruses-15-00968-t005_Table 5</object-id><label>Table 5</label><caption><p>PCR-based detection of JCV in CSF specimens from patients with organ transplantation, solid cancers, and other diseases.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Category</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Subcategory <sup>a</sup></th><th colspan="3" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Entire Period (FY2011&#8211;2020)</th></tr><tr><th colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">No. (%) of JCV-Positive Cases <sup>b</sup></th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">% of Category <sup>c</sup></th></tr></thead><tbody><tr><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Organ transplantation</td><td align="center" valign="middle" rowspan="1" colspan="1">Kidney</td><td align="center" valign="middle" rowspan="1" colspan="1">9/32</td><td align="center" valign="middle" rowspan="1" colspan="1">(28.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">75.0</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Liver</td><td align="center" valign="middle" rowspan="1" colspan="1">2/12</td><td align="center" valign="middle" rowspan="1" colspan="1">(16.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">16.7</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Lung</td><td align="center" valign="middle" rowspan="1" colspan="1">1/1</td><td align="center" valign="middle" rowspan="1" colspan="1">(100)</td><td align="center" valign="middle" rowspan="1" colspan="1">8.3</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Heart</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td></tr><tr><td rowspan="7" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Solid organ tumors</td><td align="center" valign="middle" rowspan="1" colspan="1">Liver</td><td align="center" valign="middle" rowspan="1" colspan="1">2/14</td><td align="center" valign="middle" rowspan="1" colspan="1">(14.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">25.0</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Hypopharynx</td><td align="center" valign="middle" rowspan="1" colspan="1">1/1</td><td align="center" valign="middle" rowspan="1" colspan="1">(100)</td><td align="center" valign="middle" rowspan="1" colspan="1">12.5</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Thymus</td><td align="center" valign="middle" rowspan="1" colspan="1">1/3</td><td align="center" valign="middle" rowspan="1" colspan="1">(33.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">12.5</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Esophagus</td><td align="center" valign="middle" rowspan="1" colspan="1">1/6</td><td align="center" valign="middle" rowspan="1" colspan="1">(16.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">12.5</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Stomach</td><td align="center" valign="middle" rowspan="1" colspan="1">1/7</td><td align="center" valign="middle" rowspan="1" colspan="1">(14.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">12.5</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Lung</td><td align="center" valign="middle" rowspan="1" colspan="1">1/25</td><td align="center" valign="middle" rowspan="1" colspan="1">(4.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">12.5</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Others <sup>d</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/34</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(2.9)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12.5</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Brain diseases</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722; <sup>e</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/25</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Heart diseases</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Lung diseases</td><td align="center" valign="middle" rowspan="1" colspan="1">Interstitial pneumonia</td><td align="center" valign="middle" rowspan="1" colspan="1">1/5</td><td align="center" valign="middle" rowspan="1" colspan="1">(20.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">100</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Others</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Liver diseases</td><td align="center" valign="middle" rowspan="1" colspan="1">Hepatitis C-related cirrhosis</td><td align="center" valign="middle" rowspan="1" colspan="1">2/7</td><td align="center" valign="middle" rowspan="1" colspan="1">(28.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">66.7</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Cirrhosis (unspecified)</td><td align="center" valign="middle" rowspan="1" colspan="1">1/2</td><td align="center" valign="middle" rowspan="1" colspan="1">(50.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">33.3</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Others</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td></tr><tr><td rowspan="8" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Kidney diseases</td><td align="center" valign="middle" rowspan="1" colspan="1">CKD (renal failure)</td><td align="center" valign="middle" rowspan="1" colspan="1">10/29</td><td align="center" valign="middle" rowspan="1" colspan="1">(34.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">62.5</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">CKD (nephrotic syndrome)</td><td align="center" valign="middle" rowspan="1" colspan="1">1/2</td><td align="center" valign="middle" rowspan="1" colspan="1">(50.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">6.3</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">CKD (nephrosclerosis)</td><td align="center" valign="middle" rowspan="1" colspan="1">1/3</td><td align="center" valign="middle" rowspan="1" colspan="1">(33.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">6.3</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">CKD (unspecified)</td><td align="center" valign="middle" rowspan="1" colspan="1">1/3</td><td align="center" valign="middle" rowspan="1" colspan="1">(33.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">6.3</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">CKD (polycystic kidney disease)</td><td align="center" valign="middle" rowspan="1" colspan="1">1/4</td><td align="center" valign="middle" rowspan="1" colspan="1">(25.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">6.3</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">CKD (chronic glomerulonephritis)</td><td align="center" valign="middle" rowspan="1" colspan="1">1/7</td><td align="center" valign="middle" rowspan="1" colspan="1">(14.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">6.3</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">CKD (diabetic nephropathy)</td><td align="center" valign="middle" rowspan="1" colspan="1">1/9</td><td align="center" valign="middle" rowspan="1" colspan="1">(11.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">6.3</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Others</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Infectious diseases</td><td align="center" valign="middle" rowspan="1" colspan="1">Non-tuberculous mycobacterial infection</td><td align="center" valign="middle" rowspan="1" colspan="1">1/1</td><td align="center" valign="middle" rowspan="1" colspan="1">(100)</td><td align="center" valign="middle" rowspan="1" colspan="1">100</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Others</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td></tr><tr><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Primary immunodeficiency syndromes</td><td align="center" valign="middle" rowspan="1" colspan="1">Good syndrome</td><td align="center" valign="middle" rowspan="1" colspan="1">4/4</td><td align="center" valign="middle" rowspan="1" colspan="1">(100)</td><td align="center" valign="middle" rowspan="1" colspan="1">66.7</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Combined immunodeficiency syndrome</td><td align="center" valign="middle" rowspan="1" colspan="1">1/1</td><td align="center" valign="middle" rowspan="1" colspan="1">(100)</td><td align="center" valign="middle" rowspan="1" colspan="1">16.7</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Chronic granulomatous disease</td><td align="center" valign="middle" rowspan="1" colspan="1">1/3</td><td align="center" valign="middle" rowspan="1" colspan="1">(33.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">16.7</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Others</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td></tr><tr><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Other diseases</td><td align="center" valign="middle" rowspan="1" colspan="1">Sarcoidosis</td><td align="center" valign="middle" rowspan="1" colspan="1">7/15</td><td align="center" valign="middle" rowspan="1" colspan="1">(46.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">53.8</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Comorbidity <sup>f</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">5/9</td><td align="center" valign="middle" rowspan="1" colspan="1">(55.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">38.5</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Amyloidosis</td><td align="center" valign="middle" rowspan="1" colspan="1">1/2</td><td align="center" valign="middle" rowspan="1" colspan="1">(50.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">7.7</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Others</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/16</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Total</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">60/308</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(19.5)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;</td></tr></tbody></table><table-wrap-foot><fn><p>Abbreviations: CKD, chronic kidney disease; CSF, cerebrospinal fluid; FY, fiscal years; JCV, JC virus. <sup>a</sup> The subcategories within each category are arranged according to the number of CSF-JCV-positive cases for the entire period. If the number of positive cases is the equal, then they are ranked in order of positive rate. <sup>b</sup> Numbers of JCV-positive cases and positive rates (%). <sup>c</sup> Percentages of subcategories in each category. <sup>d</sup> One patient with JCV-positive CSF had germ cell tumor. <sup>e</sup> The minus symbol indicates not applicable. <sup>f</sup> This subcategory includes cases with multiple underlying conditions whose relationship to each other could not be determined from the information in the questionnaire.</p></fn></table-wrap-foot></table-wrap></floats-group></article></pmc-articleset>